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1 Abstract  
For the ascending class of hydrophilic, macromolecular drugs, gelatin based nanocarriers 
are a very promising approach for the application as drug delivery systems. Due to the 
chemical characteristics and instability of drugs in biological fluids, their embedment into 
carriers is crucial for most biologicals. For the successful application of nanoparticles (NPs) 
physicochemical parameters, such as size, shape, surface chemistry and mechanical 
properties, are vitally important. In the present thesis the elasticity of crosslinked gelatin 
NPs is determined in Young´s moduli by the nanoindentation method in scanning probe 
microscopy. The influence of storage and different crosslinking time are investigated in 
regard to the particles’ stiffness. Here the biological relevance of the mechanical 
characteristics is tested in vitro. 
In order to avoid an inactivation, caused by the covalent coupling of the drug to the 
gelatin by a crosslinker, an innovative stabilization approach was taken by coating or 
embedment of freshly prepared, uncrosslinked gelatin NPs. Therefore, a formulation for a 
new platform delivery system, based on biodegradable and biocompatible materials, was 
developed. This was evaluated as a non-viral vector for gene delivery by the entrapment 
of locked nucleic acid and in transfection studies using a plasmid coding for green 
fluorescent protein. The exact polymer distribution was investigated in cryo transmission 
electron microscopy and energy filtered transmission electron microscopy. 
2 Kurzzusammenfassung 
Für den Transport von hydrophilen makromolekularen Wirkstoffen stellen 
Gelatinenanopartikel (GNP), aufgrund der Eigenschaften von Gelatine und deren 
Biokompatibilität, eine vielversprechende Möglichkeit dar. Eigenschaften wie 
Partikelgröße und -form, Oberflächenbeschaffenheit und mechanische Aspekte spielen 
eine Rolle in Bezug auf die zelluläre Aufnahme sowie Verteilung und Verweildauer der 
Partikel im Körper. In der vorliegenden Arbeit wurde die Elastizität von quervernetzten 
GNP als Young´s Moduli durch Nanoindentation im Rasterkraftmikroskop ermittelt. 
Darüber hinaus wurde der Einfluss der Quervernetzungszeit und der Lagerung auf die 
Partikelhärte getestet. Die biologische Bedeutung der Elastizität wurde durch die zelluläre 
Aufnahme in A549 Zellen untersucht. In einem weiteren Schritt wurde an einer 
innovativen Stabilisierung für GNP gearbeitet, bei der auf das bisher unausweichliche 
Kurzzusammenfassung   
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Quervernetzen verzichtet wurde. Dadurch soll eine mögliche Wirkstoffinaktivierung durch 
eine kovalente Bindung an Gelatine mittels Quervernetzer umgangen werden. Für die 
Formulierung wurden ausschließlich biokompatible und bioabbaubare Polymere 
verwendet. Die Eignung hinsichtlich der Nutzung als non-viraler Vektor wurde mittels 
Beladung von locked nucleic acid und der Transfektion von, mit grün fluoreszierendem 
Protein codierendem Plasmid, beladenen Partikeln evaluiert. Außerdem wurde eine 
Strukturanalyse mittels kryo-Transmissionselektronenmikroskopie (TEM) und 
energiegefiltertem-TEM durchgeführt. 
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3 Introduction 
The progress in research and technology opened up the discovery of biochemical 
processes, gene defects, and receptor specifications associated with diseases. The 
possibility to solve protein structures by crystallography helped identifying new potential 
drug binding sites and enabled a structure based drug discovery.1 This development, 
coupled with rapid progress in biotechnological methods, promoted the investigation in 
hydrophilic macromolecular drugs as a new class of therapeutics. Biologicals are 
characterized by very specific binding properties and a high potency, which opens the 
possibility to treat and cure new diseases with reduced undesired pharmacological 
effects. From the approval of the first recombinant insulin in 1982, drugs developed 
further from pure proteins to monoclonal antibodies, interferons and nucleic acid 
therapeutics.2 Despite all these progresses and advantages in therapy, biotherapeutics 
are often very unstable in biological fluids and due to their hydrophilic characteristics and 
the high molecular weight they lack the ability to be easily absorbed after administration.3 
This results in a low bioavailability which has previosly caused the termination of clinical 
and preclinical studies of once promising treatment candidates.4 Overcoming these 
drawbacks presents a challenging task in research.  
Nanostructured delivery systems, composed of biocompatible and biodegradable 
materials, are a very promising approach, which already led to market releases such as a 
depot formulation for the luteinizing hormone-releasing hormone leuprolide (Lupron 
Depot®).5 Favorable materials for the delivery of biotherapeutics are hydrophilic 
polymers, such as gelatin, which show superior loading rates compared with more 
lipophilic materials, like poly lactic-co-glycolic acid or polycaprolactone.6 Due to the 
excellent characteristics including the classification as safe material from the U.S. food 
and drug administration (FDA)7, the biodegradability to nontoxic metabolites, the 
biocompatibility or the easy availability of the raw material, gelatin is an ideal material for 
the encapsulation of hydrophilic drugs and use as a drug delivery system.8 Therefore, in 
the present thesis gelatin nanoparticles (GNPs) for the delivery of hydrophilic 
macromolecules are investigated. In order to alter the interaction with cells, the 
distribution in organs and the half-life time nanoparticles´ shape, size and surface 
characteristics are well known parameters, which can be addressed. In more recent years, 
the mechanical properties of nanoparticles (NPs) and their influence on in vitro and in 
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vivo application gained in interest.9 The development of a measurement protocol for first 
investigations of elastic moduli of GNPs is part of this thesis. In the wake of this, the 
effects of crosslinker incubation times and storage have been addressed. The resulting 
influence in elastic moduli was studied in regard to the influence on particle-cell 
interactions. Therefore, the cellular uptake of crosslinked GNPs (cGNPs) into the 
adenocarcinomic human alveolar basal epithelial cell line A549 was investigated. All 
current formulation methods for GNPs have in common an inevitable chemical 
crosslinking step directly after production.8 This unspecific reaction can covalently bind 
the biotherapeutic and thus, hinder the interaction with the target. To evade the 
inactivation through the crosslinkage, an innovative formulation strategy by the 
embedment of freshly produced GNPs in a core forming polymer could already be 
achieved with Eudragit® E 100.10 The material conversion to an exclusive use of 
biodegradable and biocompatible polymers is addressed in the second part of the thesis. 
The formulation development is amongst others, accomplished with investigations of the 
system as a non-viral transfection vector and a structure analysis was performed using 
innovative imaging methods, such as cryo- transmission electron microscopy and energy 
filtered transmission electron microscopy, a method for element specific imaging in the 
nanometer range. 
3.1 Nanoscale Carrier Systems for Drug Delivery 
 Need of Drug Delivery Systems 
Hydrophilic macromolecules as active pharmaceutical ingredients (APIs), such as 
peptides, recombinant therapeutic proteins, enzymes, monoclonal antibodies and 
antibody-drug conjugates gained immense in importance.5 The market share for 
biologicals was already more than one third of the top 100 medicines available only on 
prescription in 2015 and is projected to increase to around the half of the marked share 
by 2022.11 Their specificity and potency is, in the most cases, superior compared to small 
chemical molecules.5 However, most biologics suffer from low bioavailability.12 In 
principle their application can be carried out through numerous routes to enter the body 
for systemic or local therapy. The most popular one is still the oral drug administration by 
tablets, suspensions, capsules, or granules. Other application examples would be 
pulmonary, parenteral, transdermal or rectal. Figure 3-1 summarizes the most commonly 
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used application routes in therapy. No matter which route is chosen, the barriers, 
exhibited by the human body, to protect itself from harmful environmental influences, 
needs to be overcome by the drug, so it can be delivered to the desired place of action. 
Up to now biologicals are mostly applied parenteral. This requires the usage of syringes 
and needles which is often associated with a low patient’s compliance. In addition, many 
biologicals require repeated administrations as they show very low half-life values of 
minutes or hours due to a fast clearance.3 This results in the need of alternative 
application routes and formulations with a sustained release to improve the patient’s 
compliance and the therapeutic efficacy. 
 
Figure 3-1: Prominent application routes in drug delivery. Adopted from: “Toxicology and clinical potential of 
nanoparticles”13, Copyright © 2011 Elsevier Ltd. 
This paragraph highlights the properties of three alternative applications and different 
hurdles, which need to be overcome for a successful und efficient therapy. Starting with 
the most common route, the oral delivery, the gastrointestinal tract (GIT) needs to be 
overcome. Even though, for orally administered drugs the patient compliance is still by far 
the best, it is accompanied with a number of challenges especially for the growing field of 
hydrophilic macromolecules.14 The large epithelial surface in the gut is covered by a 
mucosal layer and in addition, the epithelial cells are connected by tight junctions. This 
exhibits an effective barrier, limiting the resorption of large and hydrophilic molecules, 
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and building a physical barrier, not only for drug application. Different drug absorption 
possibilities are illustrated in Figure 3-2. Due to the hydrophilic properties and size, 
passive diffusion is very limited. Intestinal protein carriers provide an active transport 
mechanism for the transcellular pathway. However, those drugs are often substrates for 
the efflux pump p-glycoprotein.15, 16 The paracellular pathway, which is possible to pass 
by less lipophilic molecules, is only surmountable for molecules smaller then 100 to 
200 Da.17 In addition to the physical barrier, the conditions in the GIT form a chemical 
barrier. In the stomach, a relatively acidic pH leads to denaturation and degradation of 
biological molecules. Furthermore, enzymatic digestion by pepsin and other degradative 
enzymes strengthen the chemical barrier.18 Different strategies are used to deliver 
peptides and proteins if they are able to be absorbed in the gut. Enteric coating, for 
example, can prevent biomolecule degradation in the stomach. With a careful selection of 
coating materials, colon targeting can be achieved where proteolytic activity is very low. 
 
Figure 3-2: Drug absorption processes in the gut for small molecules and macromolecular drugs. Reprinted with 
permission from: ”Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: Strategies 
and industrial perspectives“,17 Copyright © 2014 Elsevier B.V. 
Another approach to bypass the physical barrier properties, would be to co-administer 
protease inhibitors and adsorption enhancers. A promising approach, not only for oral 
delivery, is the protection in particle systems such as nanoparticles, microparticles, 
liposomes and exosomes. With the appropriate choice of excipients, mucoadhesive 
formulations can be achieved. A non-formulation-based concept is chemical modifying 
drugs with the aim to enhance membrane permeability and chemical stability. These 
strategies can be used either alone or in combination but up to now, no matter which 
approach is chosen, the bioavailability of hydrophilic macromolecules after oral 
administration remains very poor.18, 19 
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Looking at the skin, with around 15 % of the total body weight20 and a surface area of 
approximately 2 m² in adults,21 it is one of the largest organs in our body. Its purpose is 
the protection of the human body and therefore, the skin is endowed with a complex 
structure and a number of functionalities. This enables the skin to preserve the body from 
chemicals, UV radiation, microorganisms and water and electrolyte loss. Additionally, it 
plays a role in immunology, regulates the body temperature, has sensory abilities and 
exhibits excretory activity.22 Beyond the barrier properties the skin, as a regulating organ, 
shows a certain permeability, which can be exploited for local and systemic delivery of 
drugs.23 Three layers can be distinguished including epidermis, dermis and subepidermal 
tissue. The outermost layer, the epidermis, constitutes the main barrier and consists of 
several layers by itself. These layers are predominantly composed of keratinocytes. In 
approximately two weeks keratocytes move through the layers and alter to annucleated, 
cornified and flat cells, the corneocytes.21 The stratum corneum is described by the so-
called “brick and mortar” model.24 The hydrophilic corneocytes (brick) are surrounded by 
a lamellar lipid matrix (mortar) and connected by corneodesmosoms, which confer 
excellent stability to the stratum corneum.25 Penetrations routes through the skin are 
summarized in Figure 3-3. 
 
Figure 3-3: Structure of the skin with their three layers (Epidermis, dermis and subdermal tissue). Three possible drug 
penetration routes are drawn in the figure (1: appendageal, 2: transcellular, 3: intercellular). Reprinted from: 
“Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue Targeting”26 (CC BY 
4.0) 
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Drugs for transdermal delivery have to fulfill certain physicochemical requirements which 
are particularly limited by the molecule size, limited to approximately 500 Da and a high 
lipophilicity, with a partition coefficient logP between -1.0 and 4.0. Furthermore, 
solubility, polarity, melting point (below 150°C) and the daily dose, which should not 
exceed a few milligrams, have to be considered.27 Due to this, hydrophilic 
macromolecules are rather unattractive molecules for transdermal delivery. However, 
because of the circumvention of the first-pass effect, the painless application and the 
possibility of a continuous administration over several hours or days with the result of a 
constant blood level, this route remains of interest and approaches to conquer the skin 
barrier have been established. Besides the chemical modification of molecules, a co-
administration of penetration enhancers can raise the therapeutic efficiency. Here usually 
solvents, which extract the stratum corneum lipids, and surfactants, breaking the lipid 
bilayer, are employed. However, with this method the transport is only optimized for 
relative small and lipophilic molecules in a satisfying manner.23 Different physical 
approaches, with the aim of an enhanced permeation have been developed. They include 
electroporation, which could be utilized for insulin,28 ultrasound, already used to apply 
heparin29 or tetanus toxoid,30 and iontophoresis, with which the delivery of leuprolide 
could be achieved in vitro.31 All physical methods in common is the need of a special 
device, which limits the application to specialized centers and therefore, are not suitable 
for daily use. Another physical strategy is the creation of micropores, which are 
considered to not damage the skin in a clinically relevant level and can be used for the 
delivery of APIs. These pores can be achieved by a laser, used in the delivery of human 
growth hormone,32 or by microneedles. Microneedle patches can be designed in different 
manners and are based on a range of materials. They can be loaded with the therapeutic 
compounds, or just be used to produce pores for drug transport of NP-formulations.33 
Polymeric NPs are known to accumulate in hair follicles.34 Several studies showed 
enhanced blood levels compared to the application of the pure drug.35 An example would 
be a transdermal delivery by the use of starch-NPs.36 The design of very soft and 
deformable carriers with sizes of approximately 150 nm is discussed to enable the 
penetration through the stratum corneum. Transferosomes® are one of the very few 
carrier systems, which succeeded to the market as a commercially available delivery 
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system through the stratum corneum.37 Nevertheless, an efficient transdermal delivery 
still remains challenging. 
Inhalative drug application is an attractive route, as it presents a needle free 
administration, evading the first-pass effect. This results in a large number of preclinical 
and clinical trials for local and systemic acting medicines.23 The lung function, which is 
primarily the gas exchange and as a result the oxygen supply, is ensured by a large surface 
area of 75 to 140 m².38 The gas exchange takes place in the respiratory zone, including 
respiratory bronchioles, alveolar ducts and alveolar sacs. For systemic treatment, the drug 
has to enter this area too. Therefore, it has to pass the conductive zone branching out 
from the pharynx and larynx over the trachea, primary bronchi, and bronchioles to the 
terminal bronchioles.38 Characteristic for the alveolar region is the thin epithelium of 0.5 
to 1.0 µm.35 To the alveolar side around 90 % of the surface is covered by AT1 cells. A very 
flat cell type, which is responsible for the gas exchange. Around 7 % are covered by AT2 
cells producing the surfactant, which reduces the surface tension. Inhaled albumin, with a 
relative large molecular weight of 68 kDa, can penetrate through the thin epithelium and 
was shown to have a maximum plasma concentration (Tmax) after 20 h.39 This makes the 
pulmonary application a very attractive route, not only for local therapy.  
 
Figure 3-4: Fate of aerosols after pulmonary application. 1) Contact with lung fluid and drug release. 2) API absorption 
through the epithelium. 3) Undissolved particles can be cleared by macrophages or mucociliary clearance. Modified with 
permission of: “Pulmonary drug delivery: from generating aerosols to overcoming biological barriers—therapeutic 
possibilities and technological challenges”40 Copyright © 2013 Elsevier Ltd. 
A critical parameter, highly influencing the deposition site, is the aerodynamic diameter. 
With deposition maxima for mass median aerodynamic diameter of around 10 nm and 
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5 µm.41 The fate of an aerosol after pulmonary deposition, and the different penetration 
possibilities through the epithelium are shown in Figure 3-4. For dry powder formulations, 
only the maximum in the micrometer range is used for drug delivery. In order to protect 
the macromolecule after absorption to the blood stream a popular formulation strategy is 
the construction of nano-structured microparticles.42 After disintegration in the lung, NPs 
can penetrate and protect the loaded drug from degradation. An approach to deliver a 
greater mass of drug is the application of rod shaped particles, composed of 
biodegradable and biocompatible materials using the asbestos frays as a model.43 Even 
though in the last years plenty of formulations for systemic acting macromolecules made 
it to the pipeline, there are still challenges to overcome. In particular the mucociliary 
clearance, the mucus barrier, the limits in dosing and the reduced permeability in 
diseased and smoking patients have to be named here.23 After conquering the application 
barrier, the stability of biologicals is in general relatively low. Enzymatic degradation by 
peptidases, proteases or nucleases, especially in blood, liver, and kidney is a factor with 
respect to fast degradation and deactivation of hydrophilic macromolecules.44 Efflux 
pumps, like the multi drug resistant protein p-glycoprotein,45 and fast elimination through 
the kidney44 play, together with the enzymatic degradation, an important role to fight 
against exogenous invasion. Here as well nanoencapsulation is a strategy to protect 
vulnerable macromolecular drugs. Chemical modification, like the methylene bridge in 
locked nucleic acid (LNA), can be a possibility to evade degradation, but LNA still lacks 
from overcoming the lipophilic cell membrane in order to be delivered to the side of 
action.46 Nanoparticles can be utilized to overcome this barrier.47 The interaction of 
nanoparticles with cell membranes and thus factors how NPs can improve intracellular 
delivery, will be discussed in detail in chapter 3.2. 
An important barrier, protecting the central nervous system, is the blood brain barrier. 
This barrier is, like the previously discussed ones, an epithelial barrier, which hinders the 
delivery of APIs to the central nervous system. Nanoparticulate approaches have been 
developed to surmount this obstacle.48 Summarizing the challenges in delivery of 
biologicals, nanoparticulate delivery systems display a promising tool in order to obtain 
effective treatments: overcoming the main barriers while using the high potency and 
selectivity of biological drugs.6  
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 Delivery Systems for hydrophilic Drugs 
As discussed above nanoscale delivery systems can enhance the therapeutic efficacy. 
Different strategies can be exploited for the design of carrier systems in this size range. To 
the common colloidal carrier systems belong liposomes,49 solid lipid nanocapsules,50 
polymer particles, or nanocapsules. Materials for the formation of drug delivery systems 
(DDSs) should be preferably biodegradable and bioerodible. In addition, a good 
biocompatibility and low antigenicity is required. It has to be considered that degradation 
products can exhibit a different toxic potential than the polymer itself. It is important that 
all arising molecules are nontoxic.51 The drug encapsulation is highly dependent on the 
interaction between API and carrier material. The often used poly(lactic-co-glycolic acid) 
(PLGA), a hydrophobic polymer, which meets the requirements for a good polymer in 
drug delivery, has the drawback of low loading rates for hydrophilic drugs.52 
Nanostructured hydrogel composites seem to exhibit superior properties for the 
encapsulation of biologicals. Characteristic for hydrogel NPs is the chemically or physically 
crosslinked polymer network, hydrated with up to 90 % water, the relative soft 
mechanical properties and a low interfacial tension to water or biological fluids.53 
Hydrogel NPs can be produced from natural or artificial polymers, both having advantages 
and drawbacks. Examples for artificial polymers are different methacrylate derivatives, 
vinyl acetate, different PEG-polymers or betaines.51 To the frequently used natural 
derived polymers belong alginate,54 chitosan,55 starch derivatives36 or proteins.56 Whereas 
the exact chemical composition and molecular weight can be well-defined and tuned 
relatively easy for artificial polymers, their monomers do often exhibit a toxic potential. 
For naturally derived polymers, this is the other way around. They often have relative 
wide ranges of molecular weights and can show batch-to-batch variations. This can result 
in less defined particle characteristics, which can be seen for some GNP preparation 
methods, as there is a relative broad size distribution.57 The advantage of natural 
materials is the low toxic potential of degradation products53 and the renewable 
resources.56  
To the large group of protein-based NPs belong animal proteins, like gelatin, collagen, 
albumin, milk proteins, silk proteins or elastin and plant proteins such as zein, gliadin, soy 
proteins and lectins.56 Due to their chemical nature, a hydrophilic backbone with 
numerous functional groups at the amino acid side chains, they offer a great number of 
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different loading mechanisms, such as electrostatic attraction, hydrophobic interaction, 
or covalent binding. In addition, this offers the possibility of various surface modifications, 
which can be used for a targeted drug delivery. Protein NPs are postulated to show a 
prolonged half-life time and sustained release. Furthermore, an enhanced stability after 
application and an increased solubility could be found due to the chemical nature. This 
can be used for an optimized bioavailability of sensitive and poorly soluble APIs.56 As the 
present thesis is primarily interested in investigations on relevant subjects for optimized 
gelatin-based nanocarriers, the material properties, strategies in the formulation of GNPs 
and the current application possibilities will be discussed in detail in the following 
chapters. 
 Gelatin as Matrix Polymer 
Gelatin, a naturally derived polymer, is a hydrophilic macromolecular polypeptide with a 
relatively wide molecular weight range of 15,000 to 250,000 Da. It belongs to the family 
of protein polymers and is derived from collagen by alkaline or acidic hydrolysis. The 
collagen can be extracted from bones, skin, tendons or pork rind. A schematic description 
of the partial hydrolysis is displayed in Figure 3-5. The sorted triple helices are disbanded 
during heating and, while cooling, become partially ordered again. 
 
Figure 3-5: Partial hydrolysis of collagen, here by heat; the macromolecular changes are in good consistency to the 
chemical hydrolysis by acids and bases. Reprinted from: “Gelatin - A versatile biopolymer“58 Copyright © 1999 - 2018 
John Wiley & Sons, Inc. 
The numerous possible collagen sources already indicate the broad variety in the collagen 
structure. All collagen types have the triple helical structure in common but length and 
position of non-helical areas are dependent on the type. The primary gelatin structure is 
given by the amino acid sequence, which is slightly different depending on the type of 
hydrolysis. An overview of the percentage composition is given in Figure 3-6. The 
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essential amino acid tryptophan is missing. Therefore, two unusual amino acids,  
4-hydroxyproline and ε-hydroxylysine can be found in the primary structure. Both are 
built by posttranslational modifications.58  
 
Figure 3-6: Percentage amino acid composition of gelatin One third is made up by glycine, the second third is made up 
by proline and 4-hydroxyproline. The other amino acids account the remaining ~33 %.58 
Due to the characteristics of the amino acids, gelatin has cationic and anionic groups 
alongside with hydrophobic areas in approximately equal ratios. Positively charged areas 
(~13 %) are built from lysine and arginine, the negative charged sector (~12 %) is 
composed by glutamic and aspartic acid and the hydrophobic part (~11 %) by leucine, 
isoleucine, methionine and valine. Glycine, contributing to the structure with one third, 
forms, in equal amounts with proline and 4-hydroxyproline the rest of the primary 
structure.8 An outstanding property is the ability of the thermoreversible gel-sol 
transition. By cooling a 0.5 % gelatin solution below 35 to 40°C the viscosity is greatly 
increasing and with further cooling the gel formation can be observed. In the beginning, a 
helix arrangement takes place driven by an accumulation of individual dissolved α-chains. 
This is stabilized by hydrophobic amino acids. In a following step, crystal formation can be 
noted by the accumulation of two and more ɑ-helices. These crystalline areas are in a 
final step stabilized by the formation of hydrogen bonds inside and in between single 
helices. Water molecules build additional hydrogen bonds between hydrophilic side 
chains containing hydroxyl-groups. The temperature of the gel-sol transition is known as 
the melting or solidification point, which usually is between 30 and 40°C.58 The gelation 
strength is a material property, which is indicated with the bloom strength. The European 
pharmacopoeia knows gelatin type A (partial acid hydrolysis, isoelectric point between pH 
6.0 to 9.5) and type B (partial basic hydrolysis, isoelectric point between pH 4.7 and 5.6) 
and includes, except of the well-known bovine and porcine resources, gelatin obtained 
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from fishes and poultry. When bones are used for the production, the European 
Pharmacopeia stipulates that skull and spinal cord have to be removed ahead of the 
manufacturing process for safety issues. The origin of the raw material should be from a 
country stated as class I and II in regard to minimize the risk of bovine spongiform 
encephalopathy. After the extraction, gelatin has to be sterilized before the use as 
pharmaceutical excipient is allowed.59 The biocompatibility is underlined by the 
classification as GRAS material by the FDA.7 The peptide bonds can be enzymatically 
cleaved into the amino acids, which are then metabolized into carbon dioxide, water and 
urea.60 Gelatin is used in pharmaceutical formulations for oral application as wall forming 
excipient in capsules, agglutinant in granules or for the encapsulation of oleic products. 
The application goes beyond the oral administration route. Gelatin can be also found in 
emergency surgery as plasma expander61, in a hydrolyzed non gelling form as additive in 
vaccines62, as gel foam in surgery for wound absorbable dressings (Gelfoam®)63 and in 
micro capsulate formulations with sustained release for example in Lupron Depot®.64 Due 
to its hydrophilic properties, the biocompatible and biodegradable characteristic, and the 
easy and cheap availability gelatin is a well-researched polymer for micro- and 
nanoparticle formation.  
 Gelatin Nanoparticles as Carrier System for Hydrophilic Macromolecules 
This versatile polymer brings ideal characteristics for the preparation of NPs for the use as 
drug delivery system. First attempts have been reported in 1978 for gelatin 
nanoparticles57 and 1985 for nanocapsules formed by gelatin.65 Up to now numerous 
works were performed to obtain improved particle characteristics and to develop various 
methods for the formation of gelatin nanoparticles. Desolvation by the addition of agents 
like acetone or isopropanol, which dehydrates the gelatin and forces the formation of 
coils, was the first approach. Due to the relative broad distribution of molecular weights 
in gelatin this method results in inhomogeneous particle sizes.57 An improvement of this 
technology is the two-step desolvation by Coester et al. where gelatin strains with a high 
molecular weight are precipitated in a first step in order to remove low molecular weight 
gelatin. After separation the gelatin is redissolved and in a second desolvation step NPs 
with a narrow size distribution were achieved.66 This relative complex and time 
consuming procedure was further improved by Ofokansi et al. By adjusting the pH and 
the temperature the initial desolvation step could be skipped.67 Other important 
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preparation techniques are the emulsification-solvent evaporation,68 the coacervation-
phase separation,69 reverse phase microelmulsion,70 self-assembly after chemical 
modification with molecules like polyethylenglycole (PEG)71 or hexanoyl anhydrides.72 
Another method, which was used in the present thesis too , is the nanoprecipitation, or 
solvent displacement method.73 This straight forward and fast method was originally 
developed for hydrophobic polymers,74 but got adopted for the production of hydrophilic 
nanoparticles made by polyvinylalcohol (PVA)75 or gelatin.73 A closer look to the principle 
of nanoprecipitation follows, as this was the technique of choice for the production of 
cGNPs in the present thesis. The method is based on two miscible solvents. In one the 
polymer is dissolved and in a second solvent, in which the polymer has to be insoluble, 
called the nonsolvent, a stabilizer is dissolved. The nonsolvent has to be present in excess. 
In this way, the polymer remains insoluble in the mixture too. The polymer solution is 
now added to the nonsolvent. Due to the miscibility of the solvents small polymer 
containing droplets arise. This spontaneous reaction is also named the “Ouzo-effect” a 
liquid-liquid droplet nucleation caused by a supersaturation, which is describing the 
turbidity of the Greek beverage “Ouzo”.76 Driven by diffusion the solvents start to mix and 
the polymer in the droplet becomes insoluble as the saturation concentration is reached. 
The values of supersaturation, the interfacial tension, the diffusion coefficients during 
nucleation, growth and the Ostwald ripening influence the final particle size, the 
concentration and the polydispersity of the particle formulation.77 An additional influence 
has the polymer concentration in the solvent and the solvent to nonsolvent ratio.78 
Furthermore, the type of solvent plays an important role on the mean particle size. Here 
the viscosity and diffusion coefficient of the solvent in the nonsolvent seem to be 
important parameters. The mixing time, easily tunable in microfluidic systems, has an 
impact on the particle size too. Shorter mixing times result in smaller NPs diameters.79 
The use of stabilizers in the nonsolvent solution prevent the freshly formed particles from 
coalescense.77 All different production approaches for GNPs in common is the need of 
crosslinking to obtain stable nanoparticles.8 A crosslinked gelatin matrix, as well as a 
closer look on a crosslinker bond by glutaraldehyde, is outlined in Figure 3-7. Different 
chemical compounds are customarily used for this purpose. Carbodiimides in combination 
with N-hydroxysuccinimide were successfully used for the stabilization of GNPs.80 Another 
possible substance is genipin.81 This compound, derived by extraction from the gardenia 
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fruit covalently connects two primary amino functions provided from the amino acid 
lysine.82 
 
Figure 3-7: Sketch of a gelatin matrix particle after crosslinking in A and in B a zoom to a glutaraldehyde crosslinking 
Enzymatic crosslinking was achieved with microbial transglutaminases connecting a 
primary amine with an amide of glutamine.83 The most popular group of crosslinkers are 
aldehydes. Dialdehydes connect two primary amino groups of lysine and hydroxylysine. 
Glutaraldehyde, which is used in the present thesis too, is a non-zero length crosslinker. 
For acid reaction conditions, a crosslinking mechanism involving the hydroxyl groups of 
proline and hydroxyproline is discussed. However, in the present study a neutral pH was 
used for this reaction, which should involve two primary amino functions and therefore, 
form a Schiff base during the crosslinking process.84 The chemical reaction is shown in 
Figure 3-8. 
 
Figure 3-8: Crosslinking mechanism of glutaraldehyde und the formation of a Schiff base, which causes autofluorescence 
of GNPs. 
The creation of the Schiff base causes an autofluorescence of cGNPs, which can be used 
to monitor the fate of GNPs in cells.85 A less toxic representative of the aldehyde group is 
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glycerylaldehyde. Crosslinkers commonly have unspecific chemical reaction. In this way 
intra- and interchain connections are built to stabilize the freshly prepared nanoparticles. 
In case of the encapsulation of drugs, providing the same functional groups, they can be 
bound covalently to the matrix and subsequently are trapped in there. To prevent the 
inactivation of the loaded API more recently an alternative stabilization method for GNPs 
was investigated. Kahn et al. embedded freshly prepared GNPs in a Eudragit® E matrix.10 
Eudragit® E, a methacrylic-acid derivate, limits the application, of the nanoparticle 
formulation, as the polymer is soluble at pH <5.0 and it is not biodegradable.86 Adjusting 
the materials to exclusively use biodegradable and biocompatible materials is part of the 
present thesis. 
Gelatin expresses sequences like Arg-Gly-Asp (RGD),87 which binds specifically to αvβ3 
integrin, a transmembrane receptor of the integrin family. The receptor is overexpressed 
in tumor tissue and is, amongst others, responsible for cell adhesion. GNPs can be used 
for a targeted drug delivery to tumor tissues using RGD.88 Gelatin nanoparticles are 
utilized for the delivery of a broad range of APIs such as anticancer drugs,89 anti-viral APIs 
like stavudine, a drug used in HIV therapy,90 antibiotics,91 proteins such as insulin for oral 
delivery92 or tetanus toxoid in vaccines.93 The versatility of application possibilities 
demonstrate the high potential of gelatin nanocarriers in disease treatment.  
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3.2 Nanoparticle Properties Influencing the Fate after Administration in Drug 
Delivery 
A multitude of particle properties is influencing the interaction of NPs with cells in vitro 
and, for a drug delivery system far more important, the fate after in vivo application.  
 
Figure 3-9: Possible strategies in carrier design for a targeted delivery in therapy and diagnostics. Reprinted from: 
“Strategies for the intracellular delivery of nanoparticles”,94 Copyright © 2010 Royal Society of Chemistry 
Hence, the biodistribution and bioavailability is highly influenced by particle attributes, 
different strategies have been developed in order to create successful drug delivery 
systems. Figure 3-9 represents an illustration of influencing factors for the interaction of 
carriers and cells. In the following section, several of these parameters will be highlighted. 
 Size of Nanoparticles 
The size of nanoparticulate formulations ranges from few nanometers to several 
hundreds of nanometers. Looking at in vitro processes the internalization into cells is, 
besides others, a size dependent process. In Figure 3-10 different routes of cellular uptake 
are summarized. Particles in the micrometer scale are taken up by phagocytosis or 
micropinocytosis. Clathrin-mediated endocytosis is the most reported internalization 
route for receptor mediated uptake of positively charged NPs with a diameter of around 
~100 nm.95 Its primary function is the nutrient uptake in eukaryotic cells and in addition, it 
is used for internalization by several viruses.96 
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Figure 3-10: Possible cellular uptake mechanisms depending on the particle size. Reprinted from: “Targeting receptor-
mediated endocytic pathways with nanoparticles: Rationale and advances”, Copyright © 2012 Elsevier B.V. 
Caveolin dependent endocytosis is the pathway for particles ranging in the size of around 
60 to 80 nm. In this signal regulated mechanism the particle becomes coated by 
caveolins, a hairpin-like structure. Caveolae are small flask-like shaped invaginations in 
the cell membrane. They can be found in endothelial cells, adipocytes, fibroblasts and 
smooth muscles.97 Furthermore, caveolae are associated with transendothelial transport 
and release of NPs in the subendothelial tissue.98 Larger particles are taken up either by 
micropinocytosis or phagocytosis. Micropinocytosis, a process driven by actin, includes 
the uptake of external fluid. The vesicles are formed by an extension of the membrane 
and have a size of 0.2 to 5 µm.99 It is mediated by growth factor receptors as well as 
particles like viruses, bacteria, apoptotic and necrotic cells.100 Through the pathway of 
phagocytosis, usually responsible for the cellular uptake of pathogens and dead cells, 
material up to 10 µm can be internalized. The emerged phagosome adopts the shape of 
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the enclosed substrate.96 Phagocytosis is mediated by receptors and can take place at 
several cell types such as epithelial cells,101, 102 fibroblasts103 and various immune cells.104 
NPs with sizes between 10 and 60 nm seem to be taken up to a greater amount.105 
Besides the effects on the cellular level a number of factors, influencing the NPs fate after 
administration, are size dependent. Particles smaller than 6 nm undergo renal clearance 
from the blood by glomerular filtration and tubular excretion.106 Particles with larger 
diameters are accumulated in spleen and liver to a greater amount. J.M. Caster et al. 
demonstrated a size dependent accumulation for particles between 50 and 150 nm.107 In 
general particles with a diameter lager than 200 nm are known to be trapped in liver and 
spleen and subsequently processed by cells of the mononuclear phagocyte system 
(MPS).108 Due to fenestrations in the endothelial blood vessel cells, nanoparticles of a size 
between 30 and 200 nm can penetrate to tumor tissue and accumulate there. This 
passive drug targeting is known as enhanced permeation and retention (EPR) effect and is 
used for contrast agents and anticancer treatment. After extravasation, small particles of 
around 20 nm diffuse deep in the tumor tissue, but are cleared from the tumor after 24 h, 
whereas bigger particles cannot pass through the extracellular matrix and remain close to 
the blood vessel.109 As blood vessels in healthy tissue form openings in the size of 10 nm 
this size should be exceeded if NPs size is used for passive drug targeting.110 Highlighting 
the delivery to the brain it seems that NPs of a size <50 nm can pass the blood-brain 
barrier.105 Regarding the sizes and in vivo distribution the formation of a protein corona, 
which can change the particle size after administration, should always be considered.108 A 
closer look to this phenomenon can be found in chapter 3.2.3 All these size depended 
events lead, together with other factors, to a broad variance in blood retention half 
times.111 
 Carrier Shape 
The vast majority of nano- and microscale carriers are formed in a spherical shape. Under 
the first investigations of in vitro macrophage interaction with differently shaped carriers 
is a study from Champion and Mitragotri.112 As can be seen in Figure 3-11 is the successful 
phagocytosis and the internalization speed dependent on the radius of the particle´s 
curvature at the first contact between macrophage and carrier.112 In follow-up studies the 
efficacy of cell adherence could be ranked according to the shape in the order  
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elongate > oblate > sphere. However the internalization showed a divergent pattern 
following oblate >> sphere > elongate.113  
 
Figure 3-11: Colored SEM images of macrophages in brown and microparticles in purple. a) Elliptical disks which got in 
contact with the high curvature side. (Scale bar = 10 µm.) b) A macrophage attached to the flat side and is not able to 
phagocyte the disk. (Scale bar = 5 µm) and c) is showing a spherical microparticle after half phagocytosis. (Scale bar = 
5 µm) Reprinted from: “Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers”112 
Copyright © 2007 Elsevier B.V. 
For extreme aspect ratios, resulting in worm-like or needle-like structure, a failure in 
phagocytosis was demonstrated. This can be used to circumvent macrophage 
clearance.114 Smaller particles seem to exhibit a less consistent behavior. Kinnear et al. 
explained this with the variety of materials, sizes, surface chemistry and the differences in 
cell types. However, for particles of a size range from 100 to 800 nm the trend shows a 
preferable uptake for disks in comparison to spheres.114 Following the interaction route, 
objects in the size range of around 20 nm, were found to have a stronger association with 
HeLa cells in disc shape. Despite this, spherical particles have been internalized to an 
greater amount.115 Particles obtained by the PRINT®-technique have been used to study 
different aspect ratios and cubes. The particles with the highest aspect ratio showed the 
fastest uptake. This is explained by the higher surface area leading to more interaction 
with the target cell.116 Decuzzi et al. studied the in vivo distribution of cylindrical, 
discoidal, hemispherical and spherical SiO2 nano-objects and found a reduced amount of 
discoidal carriers in the liver. The high amount of this shape in organs like the lung or 
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heart is explained by the evasion of clearance by Kupffer cells after retention in the 
liver.117 So-called filomicelles with a cross-section between 26 - 60 nm and a length from 2 
to 18 µm have been proven to persist significantly longer in blood circulation of mice and 
confirm previous findings about an altered biodistribution profile.118 Beyond this, shape 
and size of gold NPs have been found to be related with the antibody formation when 
used as adjuvant in vaccines. The efficacy could be inversely related to the specific surface 
after comparing spheres and rods with diameters of 20 and 40 nm respectively.119 In our 
lab the shape effect of microrods is used for pulmonary delivery. Kohler et al. developed a 
template assisted method to produce nanostructured microrods of a well-defined size 
and aspect ratio,120 which have subsequently been developed and recently showed to be 
able to target pulmonary macrophages in order to manipulate them in the context of 
immunodesease.121 These studies show the ability of improving the efficacy of carrier 
systems by a careful selection of the shape, alongside with the other physicochemical 
parameters, in the accordance to the target side.  
 Surface Chemistry 
The in vitro uptake rate of nanoparticles was shown to be faster for positively charged 
NPs in comparison to particles with a neutral or even negative surface charge.122 
Electrostatic interactions between the negatively charged cell membrane and the carrier 
system are postulated to be responsible for this diversity. In addition, positively charged 
chitosan NPs have been proofed to be able to be released from the lysosome, after 
phagocytosis, whereas particles with a neutral and negative surface charge remained in 
there.123 In a recent study it could be shown that a change of surface decorating 
molecules alters the deposition and the cellular internalization after convection-enhanced 
delivery to rat brains. This can be used for a targeted delivery to tumors.124 Surface 
decoration by coupling of various molecules such as antibodies, carbohydrates or tumor 
markers is a popular method to biofunctionalize NPs. In Figure 3-12 the most common 
strategies are summarized. Peptides can be used to enhance the delivery into the 
cytoplasm and cell nucleus, but as well for an aimed accumulation in specific tissues. 
Magnetic NPs, presenting antibodies or antibody fragments on their surface, can be used 
as in vivo diagnostic tools.125 
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Figure 3-12: Common surface functionalization methods to enhance the efficacy of nanoparticles in drug delivery and 
diagnostics by a targeted NP delivery and prolonged blood circulation. Reprinted from: “Revisiting 30 years of 
biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine”125 Copyright © 2014 Conde, 
Dias, Grazú, Moros, Baptista and de la Fuente; 
After invading in an in vivo system NPs come in contact with liquids of complex 
composition no matter which administration route was chosen. Proteins and 
apolipoproteins are known to interact with nanomaterials and form a protein corona, 
which affects the particle size but also the surface composition and the recognition by the 
immune system.126, 127 Different approaches are used to avoid, or at least minimize, the 
interaction with proteins and clearance strategies after administration. The most popular 
strategy for sure is the formation of so-called stealth-particles. Composites with a PEG 
decorated surface showed a prolonged circulation time when a dense PEG-chain pattern 
could be achieved.128 Yang et al. showed a reduced macrophage phagocytosis and 
unspecific interaction with red blood cells (RBCs). The in vivo distribution was highly 
dependent on the molecular weight of the PEG chains and needs to be relatively high for 
a successful circulation prolongation.129 Other studies, examining the difference in the 
protein corona composition, showed a higher content of complement and coagulation 
proteins for PEGylated poly(glycidyl methacrylate) NPs, whereas the apolipoprotein 
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content was significantly decreased.130 An innovative strategy to produce long circulating 
NPs is the formation of zwitterionic surfaces. This could be shown to protect NPs from cell 
uptake and reduce the plasma protein interaction with the formulation.131 In order to 
obtain increased delivery efficiency, the surface properties have been further improved, 
to achieve a trigger-related change in the surface charge. During their blood circulation, 
the zwitterionic properties are of high advantage. The lower pH in tumor tissues, caused 
the formation of cationic particle interface, results in an improved cell uptake.132 All these 
studies show the importance of a carefully designed particle surface, according to the 
targeting side, to obtain an effective delivery system. 
 Mechanical Properties 
The impact of the mechanical carrier properties just gained attention in the last decade. 
Although it is a particle characteristic, about which the knowledge is up to now relatively 
low, its influence is as important as other particle properties. Looking in detail to the in 
vitro interactions, an enhanced and faster uptake for particles with a higher elastic 
modulus, possibly calculated as Young´s modulus, can be seen.133 In more detail, Banquy 
et al. studied the effect of mechanical properties in macrophage cell uptake with NPs 
made by N,N-diethyl acrylamide and 2-hydroxyethyl methacrylate with hydrodynamic 
diameters of 150 to 170 nm and Young´s moduli from 18.08 to 221.39 kPa. By the use of 
specific inhibitors for different uptake mechanisms, a correlation between the mechanical 
properties and the uptake route could be achieved. While hard particles have been 
predominantly taken up by a clathrin-mediated process, soft particles have been 
preferentially absorbed by micropinocytosis and particles of intermediate Young´s moduli 
showed multiple uptake routes resulting in an overall higher uptake.134 Other studies, 
investigating in the role of NP uptake by macrophages, demonstrated a higher uptake of 
stiffer particles.9, 135 The same tendency can be found in endothelial cells where a higher 
uptake into human lung microvascular endothelial cells (HMVEC)136 and human umbilical 
vein endothelial cells (HUVEC)137 was reported. Even though other studies showed more 
diverse results the majority of investigations confirm the higher and more rapid uptake of 
harder NPs into endothelial cells.133 A pronounced heterogeneity in the results can be 
found for cancer cells, typical target cells for nanoparticulate drug delivery. 
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Figure 3-13: Model of the uptake of rigid NPs in a) and soft NPs in b) showing the particle deformation during cell 
wrapping for soft particles. Rigid particles are completely internalized whereas soft counterparts are trapped at the cell 
surface. From “Tunable Rigidity of (Polymeric Core)–(Lipid Shell) Nanoparticles for Regulated Cellular Uptake”137 
Copyright © 1999 - 2017 John Wiley & Sons, Inc. 
Here the variation in cancer cell types and in the absolute Young´s moduli of the 
investigated NPs can explain the broad distribution in findings.133 Taking into account 
shape and mechanical properties Alexander et al. compared the uptake of hard and soft, 
cubic and spherical nanosized carriers with the result of an enhanced uptake for cubic 
particles in comparison to spheres. In both cases the uptake was higher for the more rigid 
formulation.136 Simulations of NPs uptake, investigating in the wrapping process, 
postulate a full and faster cell membrane wrapping for stiff particles, whereas softer 
particles might even only be wrapped partially due to particle deformation during the 
uptake process. This is explained by a lower adhesion energy needed for the uptake of 
stiffer particles.138 The postulated carrier deformation during membrane wrapping is 
illustrated in Figure 3-13.137 Anselmo et al. showed a prolonged in vivo circulation time for 
softer hydrogel NPs composed of poly(ethylene glycol) diacrylate (PEGDA) with different 
polymer volume fractions. They produced NPs with a size of around 200 nm and bulk 
moduli ranging from 10 kPa to 3 MPa. The distribution half-life (ɑ-1) was 1.48 h for soft 
and 0.11 h for hard particles in mice. Same tendency was seen in the elimination half-life 
(β-1) with 61.4 h and 9.7 h respectively. This is resulting in a longer circulation time in the 
blood for softer particles. After 12 h the differences in the organ distribution were nearly 
adjusted.9 In another study Merkel et al. studied the effect of elastic properties of 6 µm-
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sized microparticles mimicking the shape of red blood cells produced by the PRINT® 
technology. Particles with a Young´s modulus of 7.8 kPa showed a 30 times longer blood 
circulation time in mice then their stiff counterparts with a Young´s modulus of 63.6 kPa. 
The biodistribution into tissue, here measured after 2 h was found to be highly 
dependent on the elastic modulus too. Softer particles penetrated less into the lung and 
in addition, harder particles triggered pulmonary embolism, which couldn´t be found in 
animals treated with the softer particles.139 A third study, which has to be mentioned 
here, is about a soft NP formulation, which shows a low accumulation in the spleen. 
Zhang et al. designed soft zwitterionic NPs composed of poly(carboxybetaine) and 
poly(sulfobetaine) with a particle size of around 250 nm. The bulk moduli are ranging 
from 0.18 to 1.35 MPa. The circulation half time, calculated by a one-compartment 
model, was between 9.1 and 19.5 h with a longer circulation for the softer NPs. A lower 
splenic filtration is postulated underlined by an in vitro model mimicking the filtration 
process. The biodistribution after 48 h showed the lowest accumulation in the spleen for 
the softest particles, whereas these NPs have been found in the highest concentration in 
the blood. All other organs seemed to uptake equivalent particle amounts.140 The trend of 
an prolonged blood circulation time, which is seen by other studies too,133 can be used in 
drug delivery for a longer drug release in blood vessels and an enhanced delivery to the 
target side and therefore, a more effective drug delivery. Beyond the prolonged 
circulation time could a reduced accumulation in different tissues minimize side effects 
and could, through a lower accumulation in the liver, avoid the elimination by MPS 
associated cells can.141 
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4 Aim and Scope of the Thesis  
The aim of the present thesis is divided in four work packages. In Figure 4-1 the 
milestones are summarized briefly. 
 
Figure 4-1: Overview over the four milestones addressed in the present thesis. 
The first work package, dealing with the investigation in Young´s moduli of cGNPs, is 
presented in its own chapter (Chapter 5 Elasticity Determination of Gelatin 
Nanoparticles). The need of these investigations is based on the influences of elasticity in 
regard to cell internalization in vitro and biodistribution in vivo.9 Although cGNPs are of 
high interest in pharmaceutical research and have, due to their characteristics, a high 
potential to be used in therapy as a drug delivery system, nothing is known about their 
mechanical properties and how they can be influenced. Here studies are performed to 
obtain first insights into the subject.  
Gelatin as drug delivery system has several outstanding advantages, beside the very good 
loading rates, which can be up to 80%, it shows excellent characteristics as a particle 
forming polymer. Nevertheless, commonly used systems are stabilized by a crucial 
crosslinking, thus the cargo can be coupled with the particle, which can destroy their 
efficacy. This substantiates the need of a new formulation stabilizing GNPs in an 
innovative way. Therefore, a formulation process with a coating or embedment of the 
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freshly produced GNPs in Eudragit ® E100 has been developed. In the selection of the 
used materials, an exclusive use of biodegradable and biocompatible materials was 
intended for a possible application in drug delivery. Thus PLGA was chosen as a coating 
polymer well-suited with respect to its degradation profile. 
The third work package demonstrates the in vitro testing to evaluate the GNP based 
system in terms of toxicity, drug load and the use as non-viral transfection vector in gene 
delivery. Here the drug delivery system was tested in regard of LNA encapsulation as well 
as transfection with plasmid DNA. 
The final work package investigates the determination of the exact inner structure of the 
final formulation. To know about the inner structure and the polymer distribution within 
a particle is an important part of the development of new formulations and helps to 
understand and eventually even foresee the particle characteristics. The results give 
feedback to the development. Thus, the evaluation of new analytical methods, such as 
energy filtered transmission electron microscopy, for the determination of the particles´ 
structure, could be used for an eventual further improvement of the platform technology. 
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5 Elasticity Determination of Gelatin Nanoparticles 
5.1 Introduction  
The importance of mechanical properties on the in vitro and in vivo fate of carrier systems 
is discussed in chapter 3.2.4.133 Although, as discussed in chapter 3.1.4, GNPs exhibit 
excellent characteristics as carrier systems for the already popular and still aspiring group 
of hydrophilic macromolecular APIs,8 nothing is known about the mechanical 
characteristics and the possibility to influence them. This is even more surprising as 
varying the crosslinking density is a common approach for the production of NPs with 
different elastic characteristics.133 This was already proven to be a possible parameter to 
adjust the elastic properties of crosslinked gelatin gels.142 In order to promote the 
development of targeted drug delivery based on cGNPs, the aim of the following study 
was to obtain first insight into the characteristics of GNPs and moreover to test the 
influence of different crosslinker incubation times on the elasticity measured as Young’s 
modulus. To complete the study the influence of storage at 4°C was evaluated. The 
determined change in the Young´s modulus was used in a follow up investigation to 
evaluate the relevance in biological systems. 
5.2 Experimental 
 Materials 
A detailed list of the used chemicals and devices is attached at the end of this thesis in 
chapter 9. Gelatin, as protein based, hydrophilic particle forming biopolymer, is already 
described in 3.1.3.  
 Fabrication of Crosslinked Gelatin Nanoparticles 
Crosslinked gelatin nanoparticles (cGNPs) were produced with the nanoprecipitation 
method which, whose principle was described in chapter 3.1.4. Gelatin was dissolved in 
deionized water at 50°C under continuous stirring. To form NPs 1 ml solution, containing 
20 mg gelatin, was dropped slowly and under continuous stirring at 750 rpm into the 
antisolvent, which consists of 15 ml acetone containing 1 ml deionized water and 2.81 % 
(w/V) poloxamer 188 as stabilizer. To obtain stable NPs the freshly formed particles were 
crosslinked with 500 µl of a 1.85 % (w/V) glutaraldehyde in acetone solution containing 
5.55 % water. The cross linker needs to be added very slowly to prevent the irreversible 
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formation of gelatin aggregates. Glutaraldehyde was incubated for 3, 6, 15 or 18 h and 
the so gained cGNPs were purified three times by centrifugation at 10,000 g for 10 min at 
15°C. 
 Size and Zeta Potential of Gelatin Nanoparticles 
Determining hydrodynamic diameters, size distribution and surface potentials are 
relatively fast measurements for initial particle characterization and therefore an efficient 
method to control and monitor production processes. Furthermore, as described in 
chapter 3.2, particles´ size and ζ-potential have a high impact on the drug delivery 
characteristics of NP-formulations. The hydrodynamic diameters and size distribution are 
determined by dynamic light scattering (DLS) which can also be referred to photon 
correlation spectroscopy too. The method makes use of the Brownian motion of particles 
below 5 µm suspended in a liquid. This suspension is illuminated by a monochromatic 
laser beam. The light is scattered by the particle motion which is related to the particle 
size. When the light hits a moving particles a slight shift in the wavelength occurs which 
causes a small Doppler shift,143 a slight change in the frequency of the scattered light. 
Smaller particles move faster, thus cause a quicker light fluctuation. By an 
autocorrelation, of the measured intensity and the time, the translational diffusion 
coefficient (D) can be calculated and converted to the hydrodynamic diameter (DH) by the 
Stokes-Einstein equation: 
𝐷H =
kBT
3πηD
           (1) 
The further variables are the temperature (T), the Boltzmann constant (kB) and the 
viscosity of the dispersant (ƞ).144 Based on a cumulants analysis defined in ISO 
22412:2017, the Z-average diameter (ZD), the intensity correlated mean diameter, and 
the polydispersity Index (PdI), a dimensionless number characterizing the particle size 
distribution width, are derived. A PdI of 0.08 is defined as relatively monodisperse, if the 
PdI becomes larger than 0.7 a very broad particle size distribution can be assumed.145 The 
surface charge of particles in liquid is approximated by the measurement of the zeta 
potential. Particles are surrounded by ions dissolved in the dispersant. This ions form two 
layers. An inner “Stern layer” with strongly bound ions and an outer region where the 
ions are less strong attached. When a particle moves a shear plane occurs, within the 
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plane the interaction between particles and ions is strong enough, so they follow the 
particle movement. 
 
Figure 5-1: Construction of a DLS measurement device with its characteristic components. Reprinted from: “DLS and zeta 
potential – What they are and what they are not?”146 Copyright: © 2016 Elsevier B.V  
The potential existing at the slipping plane is the ζ-potential. Particles and emulsion 
droplets with a zeta potential greater than (+) 30 mV or lower than (-) 30 mV are 
considered to form a stable formulation as they repel each other when they come too 
close.147 Zeta potentials are strongly influenced by the pH of the dispersant. For proteins 
the potential is positive at pH values below the isoelectric point (IEP) and negative if the 
pH is higher. For the measurement an external electric field is applied. This results in an 
electrophoretic mobility which can be used for the determination of the zeta potential. 
Viscous effects of the medium work in the opposite direction. In the state of equilibrium 
the particle moves with a constant velocity which is influenced by the electric field 
strength, the dielectric constant of the medium, the viscosity and the zeta potential. The 
zeta potential can be measured by the laser Doppler velocimetry (LDV) which measures 
the fluctuation of scattered light in an electrophoresis experiment in the angle of 17 
degree and compare this with a reference beam. The fluctuation is proportional to the 
particle speed. Another method is the M3-PALS. A combination of phase analysis light 
scattering (PALS) with mixed mode measurement (M3). This is the combination of a slow 
field reversal and fast field reversal of the electric field to compensate a possible shift of 
the determined zeta potential through electro osmosis, a movement of the surrounding 
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phase in the applied electric field. The use of PALS improves the results especially for 
samples with low particle mobility as the phase shift is more sensitive than the frequency 
shift used in LDV.  
To determine the hydrodynamic diameter, the particle size distribution and the zeta 
potential a NanoZS zetasizer was used. The device operates in the non-invasive back-
scatter technology (NIBS) for the size measurements and M3-PALS to determine zeta 
potentials.148 Samples have been prepared by dilution with purified water in a ratio of 
1:20 to obtain a suitable particle concentration. A disposable folded capillary cell (type 
DTS 1070) was used for the measurement. All samples have been evaluated immediately 
after purification and after four weeks of storage at 4°C. 
 Electron Microscopy 
5.2.4.1 Visualization of the NP Morphology by Scanning Electron Microscopy 
With the development of the scanning electron microscope a resolution down to the 
nanometer scale got accessible. The investigated area is scanned by a small electron 
beam produced by a cathode and accelerated with an anode at a defined voltage. 
Cathodes are either made of lanthanum hexaboride (LaB6) or tungsten. The electron 
beam is focused by electric or magnetic condenser lenses. A scan coil, located above the 
objective lens, controls the position of the beam and thus allows the beam to scan the 
sample in X and Y directions. The set-up is displayed in Figure 5-2. To avoid interactions 
with atoms, before reaching the sample surface, the whole set up is placed in a vacuum 
chamber. When the electron beam reaches the specimen, different interactions between 
the electron beam and the sample are occurring.  
 
Figure 5-2: Typical construction of a scanning electron microscopy machine, Copyright © 2009 How stuff works 
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For imaging typically either secondary electrons, which are scattered inelastically from 
the interaction with electrons close to the surface (<2 nm) or back scattered electrons 
(BE), which arise from elastic interaction with the nuclei, are used. As BE electrons have a 
higher energy, they can be detected from deeper levels of the sample. Using secondary 
electrons the scanning electron microscopy (SEM) represents a very good method for 
surface morphology examinations.149 More electron beam-specimen interaction will be 
described later in chapter 6.2.5.3. Samples have been prepared on a silica wafer which is 
attached to a pin stub with a carbon disk. Approximately 50 µl of NP suspension was 
dropped on the wafer. 
The drop was incubated for one minute, in order to let the NPs adsorb to the surface, 
before the supernatant was removed with a lint-free tissue. To gain an electro conductive 
surface, which is required for imaging, a 10 nm gold layer was sputtered in a Quorum 
Q150R ES sputter coater to prepare GNP samples for imaging in an EVO HD15 SEM using 
an acceleration voltage of 5.0 kV and the secondary electron image (SEI) detector. 
5.2.4.2 Transmission Electron Microscopy 
The principle of transmission electron microscopy (TEM) will be explained in chapter 
6.2.5.2. For sample preparation 50 µl of a particle suspension was dropped on a holey-
carbon film (Plano S147-4). The dispersant was evaporated completely before imaging in 
a JOEL JEM 2100 TEM. For electron generation a LaB6-cathode was used and for imaging 
a Gatan Orius SC100 camera. 
 Scanning Probe Microscopy 
5.2.5.1 Principle of Scanning Probe Microscopy 
The scanning probe microscope (SPM), also called atomic force microscope (AFM), is a 
microscope which scans the surface of a specimen with a probe, mounted on a cantilever. 
The technique was invented in 1986 by Binnig and colleagues150. The resolution in x, y and 
z direction is outstanding with the possibility to resolve from micrometers down to the 
angstrom scale. To detect the cantilevers deflection a laser beam is used. The back side of 
the cantilever reflects the beam which is then brought over a mirror to a position-
sensitive photodiode (PSPD). This principle is called the optical lever arm, as a small 
cantilever displacement is magnified in a relative large beam motion on the detector.151 
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An illustration of a SPM machine is shown in Figure 5-3. Every cantilever displacement will 
cause a change in the position where the laser beam hits the PSPD. 
 
Figure 5-3: Schematic of a scanning probe microscope. 
Two imaging methods are commonly used. In the contact mode the probe is always in 
touch with the sample. While scanning the specimen line by line, either the cantilever 
deflection can be measured or, in order to keep the force on the sample gentler, the 
feedback signal needed to keep the deflection constant, is measured. For measurements 
in ambient air, the capillary forces, produced by a thin water film on the sample, are very 
strong. This can be eliminated by measurements in liquid. The second mode, the tapping 
or intermittent contact mode, makes use of a cantilever oscillating with a frequency, close 
to its resonance frequency. At the minimum of the oscillation amplitude, the tip is in very 
brief contact with the specimen surface. If the cantilever is very close to the surface, 
different forces (van der Waals forces, dipole-dipole interactions, electrostatic forces) are 
impinging on the cantilever and therefore influence the amplitude. In order to keep the 
cantilever amplitude constant these forces go into the feedback loop, controlling the 
cantilever height. As the surface is only touched very shortly, the damage to the specimen 
is reduced in comparison to contact mode measurements. The repulsive and adhesive 
forces have an influence on the frequency and result in a phase shift, which is influenced 
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by the surface characteristics. In this way differences in surface composition, which 
cannot be seen in the height profile, are accessible.152 Even gentler, as the tip does not 
come in contact with the specimen, is the third possibility, the noncontact mode. This 
mode makes use especially of van der Waals forces. Oscillation amplitudes of less than 
10 nm are used. Van der Waals forces are usually the strongest from 1 nm to 10 nm 
distance to the surfaces. In this mode the distance between tip and cantilever are kept 
constant. The options to run SPM measurements under various conditions (ambient air, 
vacuum, different gases and liquid) and from low to high temperatures open a broad 
range of possibilities. In liquid even the imaging of living cells is possible.153 In addition, 
the water capillary forces which are present in ambient air condition at the tip-sample 
interface are removed.154 For the purpose of characterization of hydrogel particles with 
the application in drug delivery, a more realistic investigation can be performed in liquid 
conditions too. The analytical capabilities of a SPM go far behind simple imaging of 
surfaces. The usage of SPM for the quantitative measurement of elastic material 
characteristics is described in chapter 5.2.5.2. Through the combination with other 
techniques such as SEM or fluorescence microscopy, the spectrum of possibilities is even 
broader. In this way the interaction between single viruses and cells could be studied.155 
5.2.5.2 Sample Preparation for SPM in Water and Air 
To perform AFM experiments under liquid conditions, the NPs needed to be fixed to the 
substrate. This could be achieved with electrostatic interactions between a positively 
coated silicon wafer and the negatively charged GNPs. Therefore silica wafers have been 
cleaned with absolute ethanol in an ultrasound bath (Elmasonic P) for 5 min at a 
frequency of 37 kHz. Afterwards, the surface was activated in UV/ozone for 15 min 
(UV/Ozone ProCleanerTM). Subsequently, the wafer was incubated with a 1 % (w/V) 
polyethylenimine (PEI; average Mw of 25 kDa) solution in deionized water. Coated wafers 
have been rinsed with filtered deionized water in which they have been kept wet and 
stored at 4°C until final sample preparation. The substrate was coated for a maximum of 
24 h before usage. Immediately before the experiment, samples have been diluted 1:3 
with deionized water and 50 µl of the dilution was transferred to the coated substrate. 
After one minute of incubation the excess was rinsed from the wafer with filtered 
deionized water in which they have been kept wet afterwards until the end of the 
measurement. For SPM topography images, taken under ambient conditions, 10 to 20 µl 
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of the sample have been applied to freshly cleaved mica. After an incubation time of 
approximately one minute the rest of the sample was removed with a lint free tissue and 
measured in intermittent contact mode after complete drying. 
5.2.5.3 Elasticity Measurements 
Scanning probe microscopes cannot only be used for topography measurements. Due to 
the possibility to measure small forces (even in the pN range) the interaction between 
materials can be investigated. Furthermore, mechanical properties of various materials 
can be determined. First nanoindentation experiments have been performed in the 
1970s. 156 Since then the technique was developed and in the 1990s adopted to the use 
by SPM. This raised the possibility to determine the elastic moduli on nanoparticles.157 A 
sketch of the simplified principle of an indentation experiment is depicted in Figure 5-4. A 
SPM probe is used to indent the NP by a piezo displacement. The displacement can be 
plotted against the force, exposing the cantilever during the indentation, resulting in a 
force-distance curve. Since the cantilever acts like a spring, the indentation depth can be 
calculated if the spring constant is determined prior to the experiment. 
 
Figure 5-4: Simplified principle of the nanoindentation performed by a SPM measurement. 
A typical example of such a curve is illustrated in Figure 5-5. Four characteristic segments 
are highlighted in this graph. The experiment starts with an approach of the SPM probe to 
the NP surface, which runs free of force. When the tip approaches close enough to the 
surface, attractive forces between probe and surface can cause a jump into contact. This 
results in a negative force. While further lowering the piezo the zero-force baseline is 
crossed again, this is the so-called contact point, which is set to the origin of the 
coordinate system. From this point on the probe indents the nanoparticle until a defined 
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setpoint force is reached. This is displayed in the third measurement segment. The 
calculation of the Young´s modulus is based on the fit of the resulting slope in this sector. 
The retract part, displayed in green, represents the lifting of the cantilever. Due to 
adhesion forces between tip and sample surface a negative force can be obtained. The 
adhesion force is a combination of the electrostatic force, van der Waals force, the 
capillary force and forces brought to the system through chemical bonds or acid-base 
interactions.157 It can be calculated by the area between the retract curve and the 
baseline. A cantilever movement without force, until the original cantilever position is 
reached, finishes the indentation loop. 
 
Figure 5-5: Typical force-distance curve of a nanoindentation experiment on cGNPs with characteristic segments. I) Force 
free approach, II) jump into contact, III) indentation of the tip into the sample, IV) retract with segment with the 
possibility to determine adhesion forces. 
All nanoindentation experiments were performed with a JPK NanoWizard I SPM. To get a 
more realistic insight in the elastic characteristics of cGNPs all experiments were operated 
under liquid conditions. A quadratic pyramidal tip of the MLCT type was used as an 
indenter. The probe is made by non–conductive silicon nitride with a gold coated back 
side. The C cantilever with a nominal spring constant of 0.03 N/m was used throughout 
the entire force-distance measurements. Directly before the measurement of a new 
sample, the thermal noise method according to Hutter et al.158 was used to determine the 
cantilever’s actual spring constant on a cleaned silica wafer. To roughly localize the 
distribution of cGNPs on the substrate an overview scan was done initially. Subsequently 
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one particle was chosen randomly and depicted closely do determine the exact position 
and be able to perform 10 force-distance measurements in the middle of the NP. After 
the fifth and tenth indentation the particle is relocalized to ensure all data are actually 
acquired in the middle of the particle. Measurement settings have been defined to an 
approach and retract rate of 3.33µm/s and an applied force of 2 nN. Ten force distance 
curves per particle on ten particles per sample, resulted in 100 data points obtained per 
sample. The obtained curves are fitted and processed by the Hertzian model. Therefore, a 
linear relation of stress to strain is obligatory. This was checked prior to the 
determination of the Young’s moduli. Therefore, forces between 0.5 and 2.5 nN have 
been applied. To extract the necessary parameters for the calculation of stress and strain 
the original jpk-data files have been converted into text files and then read out with the 
AFMToolkit in R Studio.159 Subsequently, the stress, defined as σ = F/A with F being the 
applied force and A the contact area between indenter and nanoparticle, is calculated 
according to the following equations. For a quadratic pyramidal tip A is composed by the 
parameters 
𝐴 = 4ℎc²
𝑡𝑎𝑛 𝛼
𝑐𝑜𝑠 𝛼
           (2) 
The tip half angle ɑ was taken from the official product description whereas the contact 
depth hc has to be calculated by:  
ℎc =
2
𝜋∗𝛥𝑙
           (3) 
Here Δl is the indentation depth which was calculated by the following equation  
∆𝑙 = 𝑧 − 𝛿c           (4) 
Where z is the piezo displacement and δc the cantilever deformation.160 As the cantilever 
can be compared with a spring, the deformation can be obtained by Hook’s law F = k* δc. 
F is the applied force and k the spring constant, which is determined in advance of each 
experiment. The strain is expressed by ε = Δl/l0. Being Δl the indentation depth defined 
in equation (4) and l0 the initial NP height. The calculated values are then plotted against 
each other and fitted with a regression line. The chosen application force of 2 nN is in the 
tested linear range and allows measurements with an indentation of less than 10 % of the 
absolute particle height. This is fundamental as infinite sample thickness is one of the 
assumptions made by the Hertz model.161  
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5.2.5.4 Evaluation of Force-Distance Curves 
To obtain the Young’s moduli from the measurement data, the curves are handled in the 
JPK-SPM Data Progressing Program (DP). Young´s moduli can be extracted by fitting the 
recorded curves, after editing1, with the Hertz model. As this is based on a parabolic tip 
an adjustment for the quadratic pyramidal tips is required. The modified Hertz model  
𝐹 = 0.7453 ∗
𝐸
1−𝜈2
∗ 𝛿2 ∗ tan (𝛼)        (5) 
is used by the DP. Where F is the applied force, E is the Young´s modulus, ν is the 
Poisson´s ratio, which is assumed to be 0.5, δ is the indentation depth and ɑ stands for 
the half angle of the tip used. To start the data processing the cantilever deflection needs 
to be calibrated by the cantilever´s spring constant and sensitivity which was determined 
prior to the measurement. The next step is the baseline subtraction to correct the vertical 
offset and subsequently the contact point can be detected. The now depicted curve still 
represents the piezo displacement, which is greater than the actual indentation into the 
particle. The difference is caused by a deflection coming from the force the cantilever is 
exposed to. This needs to be corrected by the tip-sample separation. The obtained force-
distance curve is steeper and can be fitted by the modified Hertz model to finally obtain 
the Young´s modulus. 
 Cellular Interaction in Dependency of Particle Stiffness  
As a consequence of the data the following experiments were realized during a diploma 
thesis at the institute by Thorben Fischer.  
The biological relevance of the change in the particle stiffness of GNPs was investigated 
with the alveolar cancer cell line A549 with 18 h crosslinked FITC-Dextran70 loaded GNPs. 
The aim of these experiments was, to investigate in the importance of the mechanical 
properties with respect to the interaction between cells and NPs. Therefore, 20 mg of 
gelatin were dissolved in 800 µl deionized water and mixed with 1 mg FITC-Dextran70 
dissolved in in 200 µl deionized water and coprecipitated in acetone containing 2.81 % 
(w/V) poloxamer 188 as stabilizer with an agitation speed of 750 rpm. Crosslinking was 
done with 500 µl of a 7.4 % (w/V) glutaraldehyde solution. After 18 h particles have been 
purified three times by centrifugation with 10,000 g for 10 min at 15°C. A549 cells have 
                                                     
1 Editing includes the baseline-correction to bring the baseline to zero-force, the correction of the contact 
point to zero-length and a tip-sample-separation. 
Elasticity Determination of Gelatin Nanoparticles   
40 
been grown in RPMI-1640 medium with the addition of 2 mM glutamine and 10 % (V/V) 
fetal calf serum (FCS) in µ-Slide 8 well ibiTreat® microscopy chambers for three days. 
GNPs have been investigated one day after production and after four weeks storage at 
4°C in water. After an incubation time of 4 h and 8 h respectively with 1.05 mg particles 
per well, cells have been washed twice with Hanks Balanced Salt Solution (HBSS) buffer. 
For the visualization in the confocal scanning microscope (CLSM) cell cores have been 
stained with 200 µl of a 10 µg/ml 4′,6-Diamidine-2′-phenylindole dihydrochloride solution 
(DAPI). N-Hydroxysuccinimid Alexa Flour® 633 was used in a concentration of 5 µg/ml to 
stain the cell membranes. Both dyes have been incubated for 15 min. To remove excess 
material, A549 cells have been washed three times with HBSS buffer after each step. The 
labeled NPs have been excited with an argon laser at 488 nm, Alexa Fluor 633 was 
detected with an argon laser too but at a wavelength of λ = 633 nm and for DAPI a laser 
diode 405-30 with a wavelength of λ = 405 nm was used. Images have been taken with M 
27 objective with a numeric aperture of 1.2 and a 40 x magnification. As CLSM is also used 
later in chapter 6.2.5.1 to colocalize different polymers a brief introduction to the 
technique is given here. 
CLSM is a light microscopy technique based on fluorescence emission, caused by 
excitation with a laser of an appropriate wavelength which scans the specimen. The 
emitted light is sectioned by a pinhole. Only light from the in-focus plane can pass 
through this partial filter unit to the photodetector. By this limitation to the focus plane 
the sample can be dissected into thin optical slices. This allows a 3D reconstruction of the 
sample from the slices acquired from different positions. Therefore, compared to normal 
light microscopy, sharper images are obtained. This method has a lateral resolution of 
around 0.23 µm and approximately 1.1 µm in the vertical direction (Calculated for Alexa 
Fluor 633 and the used settings). To image cells or tissue the specimen has to be labelled 
fluorescently with dyes or with antibodies bound to a relevant dye. By scanning the 
sample with different lasers and the corresponding appropriate dyes, diverse information 
about the region of interest can be assembled in one image.162 As the focus can be varied 
through the specimen, pictures from different planes can be obtained. Moving the focus 
plane stepwise through the sample allows assembling a so-called z-stack. From this, a 3D 
image can be digitally reconstructed. 
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5.3 Results and Discussion 
 Sizes and Zeta Potential of Gelatin Nanoparticles 
For all crosslinking times the hydrodynamic diameters, particle size distributions and ζ-
potentials have been determined with a zetasizer Nano-ZS. The results are combined in 
Figure 5-6. The sizes and PdIs stayed constant over the range of glutaraldehyde 
incubation times and the storage period. All formulations show a mean for the 
hydrodynamic diameter between approximately 300 to 350 nm. For the PdIs of around 
0.2 the particle size distribution can be assumed to be narrow but not monodisperse.145 
The constancy in regard of size and PdI supports a stable nanoparticulate formulation. 
 
Figure 5-6: Sizes and PdIs of cGNPs after 3, 6, and 18 h of crosslinking. One day after production (fresh) and after four 
weeks of storage at 4°C (aged) in a). In b) the ζ-potential for the same formulations is displayed. 
In Figure 5-6 b) the zeta-potentials are shown. Here a decrease of around 5 mV from 
approximately -20 mV to -15 mV can be measured. With p < 0.05 this change was stated 
to be significant. A possible explanation for this can be the triple helix formation over 
time. These helices are stabilized by hydrogen bonds either formed between a carboxylic 
and an amide group or, with a water molecule as linker, between two carboxyl groups. As 
negatively charged CO-functions are involved in the helix stabilization, they cannot 
contribute to a negative surface charge anymore.163, 164, 165 
 Visualization of Crosslinked Gelatin Nanoparticles 
To check the morphology and shape, cGNPs have been visualized in SEM, SPM and TEM. 
For all images in Figure 5-7, cGNPs have been captured in dried conditions. SEM in a) and 
TEM in b) under high vacuum. The SPM image in c) is taken in tapping mode at 
atmospheric conditions. The round particle shape is clearly visibly. In the TEM image the 
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homogeneous material distribution throughout the entire particle is apparent. The 
height, determined after SPM measurements of 28 nm, shows the hydrogel particles 
collapse while drying. Comparing the SPM cross-sections in Figure 5-8 of cGNPs imaged in 
air and in deionized water demonstrates the superiority of SPM images taken under liquid 
conditions which is the only method to get realistic values about the 3D occurrence of 
hydrogel nanoparticulate formulations. 
 
Figure 5-7: Visualization of cGNPs a) in SEM, b) in TEM, c) in SPM. SEM and TEM under high vacuum and SPM in air at 
atmospheric pressure. Particles are roundly shaped and have a smooth surface. 
In SPM-cross-sections the 3D shape is easily accessible. Two of them are displayed in 
Figure 5-8. In a) from a NP captured in air and in b) from a SPM measurement performed 
in liquid conditions. Comparing the y-axes the advantages of the liquid surrounding is well 
visible. In air a height of approximately 28 nm remains whereas the height in liquid meets 
with 140 nm nearly the same value than the diameter (175 nm). A possible indication of 
the slightly smaller height in comparison to the diameter is a compression caused by the 
SPM probe during the measurement. 
 
Figure 5-8: SPM visualization and analytics of cGNPs captured in liquid (b) to e)). a) shows a representative cross-section 
through a crosslinked gelatin NP imaged in the dry state in air. The attention has to be at the y-axes showing the particle 
collapse during drying in a) whereas the particle in b) keeps the spherical form. 
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The SPM images in Figure 5-8 are showing 2D and 3D views of particles imaged in 
deionized water in c) and d) respectively. The height of particles measured in liquid meet 
the expectations gained from particle size determinations. Figure 5-8 e) shows a close 
zoom to a single cGNP captured in water. The black bar indicates the line of the cross-
section in b). 
 Elasticity Determination – Force-Distance Measurements 
To get first insights in the mechanical properties of cGNPs nanoindentation experiments 
have been performed. The first step in the elasticity determination of a new system is to 
check for linearity. As described above forces of 0.5 to 2.5 nN have been tested and 
evaluated for their stress to strain correlation. The results are summarized in Figure 5-9 
for 3 h incubated cGNPs in a) and 18 h in b). Both formulations show a linear dependency 
what is supported by correlation coefficients of 0.928 and 0.964 respectively. This proofs 
that the calculation of Young’s moduli can be done with the help of a Hertzian fitting. A 
force of 2 nN was chosen for the further investigations because it is in the examined 
linear range and allows a stable measurement without being susceptible to external 
influences and meets the requirement of an indentation of less than 10 % of the original 
height.161 
 
Figure 5-9: Linear dependency of stress and strain of particles crosslinked for 3 h in a) and 18 h in b). The correlation 
coefficients are 0.928 for A and 0.964 for B and therefore proofing the linear dependency of stress and strain. 
Subsequently to the proof of linearity cGNPs have been investigated in regard of their 
Young’s moduli. As can be seen in Figure 5-10 cGNPs crosslinked for 3, 6 and 18 h are 
examined one day after production and after four weeks of storage at 4°C in water. For all 
fresh formulations a Young’s modulus of 30 to 35 MPa could be calculated. Whereas 
there was no detectable difference in stiffness between the fresh particles a clear 
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influence of storage could be verified. This alteration is more pronounced the longer the 
crosslinking time was; ranging from 36 % for 3 h crosslinked particles and over 62 % to 
129 % for 6 h and 18 h-crosslinked particles respectively. Overall, the change in the mean 
mechanical properties was found to be significant by two-sided student’s t-tests with p < 
0.0055 (Bonferroni adjustment). 
 
Figure 5-10: Young’s moduli of cGNPs crosslinked for 3, 6 and 18 hours one day after production and after 4 weeks of 
storage.  
It was expected to see a difference in the mechanical properties of fresh cGNPs as a 
correlation between crosslinking extend and the elastic behavior of gelatin gels could 
already be demonstrated.142, 166 Possible explanations why no change could be observed 
are, that either the particles are fully crosslinked after three hours, or the slight increase 
is too small to be detected. Shorter crosslinking times have to be addressed to check for 
the possibility of the formation of softer cGNPs. However, particles crosslinked for less 
than three hours could not be purified by centrifugation and because of that haven´t 
been considered in this study in order to keep the conditions constant. Methods like 
dialysis, size exclusion or cross-flow filtration would need to be established for cGNPs to 
study the influence of shorter crosslinking times or lower cross linker concentrations. As 
the production procedures should be kept as constant as possible, in order to exclude 
possible changes in the resulting particles, this was not done in the present study. 
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Looking in detail to the hardening over the storage time, it can be said that this was 
already studied for solid gelatin films167 but up to now never was taken in account for 
gelatin nanoparticles. A possible effect leading to the enhanced stiffness is the formation 
of triple helices. Triple helices are thermodynamically preferred. Therefore, gelatin has 
the tendency to form these crystalline areas until the equilibrium between the breakage 
and the formation of new stabilizing hydrogen bonds is reached.163, 164, 165 
 Cellular Interaction in Dependency of Particle Stiffness 
The biological relevance of the change in the elastic modulus while storing the 
formulation was tested in qualitative and quantitative interaction studies of 18 h 
crosslinked cGNPs with A549 cells. The qualitative interaction study was evaluated by 
CLSM. The quantitative data was obtained according to the protocol described in Shi et al. 
2015.168 
 
Figure 5-11: CLSM image of stained A549 cells after 8 h incubation with FITC-dextran70 loaded cGNPs. In a) cGNPs have 
been used one day after production and in b) cells are incubated with four week old cGNPs. cGNPs are displayed in 
green, cell cores in blue and cell membranes red. 
The CLSM images in Figure 5-11 display the cellular interaction with FITC-dextran loaded 
cGNPs is investigated after 8 h of NP incubation. In terms of cellular internalization a clear 
advantage of the aged particles displayed in b) was visible. Particles were counted in 
relation of cell numbers in at least five pictures of fresh and aged cGNPs. In comparison to 
the fresh formulation the amount of interacting NPs increased 4.8 fold. These results 
have been further investigated for quantitative cell uptake; here the measured increase 
after 8 h was 4.2 fold. Both methods result in a similar outcome. However, after 24 h the 
cellular interaction of fresh and aged particles was nearly aligned. The results show the 
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need of further investigations of both changes in the elastic moduli of cGNPs and the 
effect to biological systems. Therefore, more time points should be evaluated so uptake 
kinetics can be calculated. In addition, other cell lines, such as macrophages and human 
noncancerous cells, have to be studied to be able to strengthen the biological relevance 
of particle stiffness. This, paired with investigations of internalization routes, could help to 
gain a better understanding of the exact role of elastic moduli for hydrogel 
nanoparticulate systems.  
5.4 Conclusion 
The value of nanosized hydrogels in drug delivery was discussed in chapter 3.1.2. In the 
present thesis the influence and the importance of the measurement conditions for 
hydrogel NPs analytic could be shown. It was possible to visualize cGNPs in liquid by 
fixation by electrostatic interactions between substrate and NPs and map cGNPs in an 
environment closer to condition after application. By the switch of visualization in SPM to 
liquid conditions it was possible to image the spherical shape in a 3D view. This is an 
impressive difference to the data obtained by measurements in air. Furthermore, for the 
first time, an insight in the elastic characteristics of cGNPs could be achieved. The use of 
the nanoindentation method in SPM and fitting the obtained force-distance curves with 
the Hertz model is a suitable method to define Young´s moduli quantitatively. The 
investigated crosslinking times had no impact on the determined Young´s moduli for NPs 
analyzed one day after production. By comparing these results with the Young´s moduli 
obtained after four weeks of storage at 4°C in water a significant increase was detectable. 
In biological studies, performed with A549 cells, the effect of NPs elastic characteristics 
on the interaction with cells was demonstrated. As the other determined physical 
chemical parameters stayed constant, the increased interaction of cGNPs over the 
observed storage time correlates with the elasticity. This underlines the outstanding 
importance of the knowledge of elastic moduli and NPs age besides size, shape and 
surface properties. By a possible tuning of the particle stiffness, the in vitro fate, and most 
likely as well the destiny in vivo, of cGNPs could be altered in order to achieve a targeted 
drug delivery and prolonged blood circulation times. Further studies are necessary to 
determine possibilities of a modified production in order to design GNPs with editable 
Young´s moduli.
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6 Stabilizing Gelatin Nanoparticles without Crosslinking 
6.1 Introduction 
The importance, which biological therapeutics gained over the last years is indisputable. 
Their outstanding specificity and potency made them to an already important and still 
growing share on the market.11 Due to their low stability in vivo and the hydrophilic 
properties,3 the development of a delivery system can prolong the circulation time and 
smuggle the drug over the multitude of lipophilic barriers resulting in an enhanced 
bioavailability. A lot of work is invested in the encapsulation into PLGA NPs. However, due 
to the hydrophobic characteristics, the loading rates are rather low.52 Due to the excellent 
characteristics of nanoparticulate carrier systems formed by gelatin, which are discussed 
in detail in chapter 3.1.4, GNPs seem to be a promising system for this purpose. To 
overcome the drawback of the still inevitable crosslinking is addressed in the following 
chapter. The described investigations are based on the possibility of an alternative 
crosslinking-free stabilization of GNPs by the embedment in Eudragit® E 100 spheres.10 
The application limitation of the non-biodegradable Eudragit® should be removed by the 
exclusive use of biodegradable and biocompatible materials to achieve the development 
of a nontoxic, biodegradable platform technology for the use as drug delivery system for 
hydrophilic macromolecular drugs. 
6.2 Experimental 
 Materials 
For the formulation of the hydrophilic delivery platform, only biocompatible and 
biodegradable materials are chosen. The main compounds are gelatin B for the 
hydrophilic part, which is already described in detail in chapter 3.1.3 and PLGA for 
stabilization of the freshly prepared GNPs.  
6.2.1.1 Poly lactic-co-glycolic acid 
PLGA is a copolymer composed of lactic and glycolic acid in various ratios. The high 
interest in pharmaceutical research is based on its biodegradable and biocompatible 
characteristics. The chemical structure of the artificial polymer is shown in Figure 6-1. 
With a variation of the ratio of lactic and glycolic acid or the polymers’ molecular weight, 
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the glass transition temperature, degradation rate and hydrophobicity are adjustable. As 
a result, the drug release changes due to the chemical composition.169, 170  
 
Figure 6-1: Chemical structure of poly lactic-co-glycolic acid. The ratio between glycolic acid (marked with the y) and 
lactic acid, (signed with the x) can vary. 
PLGA is degraded in its monomers, lactic and glycolic acid, by hydrolysis. They are then 
eliminated through the Krebs cycle as carbodioxid or along the renal pathway. The 
degradation process is highly dependent on temperature, pH and, under controversial 
discussion, enzymes.171, 172 First sustained drug delivery systems based on PLGA have 
been introduced in the 1970s for naltrexone, an opioid antagonist173 and for 
microcapsules loaded with norethisterone, a contraceptive agent.174 Nanoparticles 
composed of PLGA gained an increasing importance since the 1990s.175 Several 
pharmaceutical products based on PLGA have been introduced to the market such as 
implants (Zoladex®) or micro particles (Enantone Depot®). The PLGA type used in the 
present thesis is the Resomer® RG 503 H. It is acid terminated, has a lactide:glycolide ratio 
of 50:50 and a molecular weight of 24,000 – 38,000. The degradation time is given to be 
three months and the glass transition temperature is stated to be between 44 and 46°C 
from the supplier. 
 Formulation Development of GNPs in PLGA 
6.2.2.1 Size and Zeta Potential of Gelatin Nanoparticles 
The hydrodynamic diameter, PdI and the zeta potential of GNPs in PLGA have been 
determined by a Zetasizer NanoZS. For size measurements, DLS with a backscatter 
detector in an angle of 173° was used. In contrast, the zeta-potential was determined 
with forward scattering at an angle of 12.8° by M3-PALS. After the last purification step 
samples were dispersed in 5 ml deionized water. Before the measurement the samples 
have been diluted 1:20 and have then been measured in disposable folded capillary cells 
of the type DTS 1070.  
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6.2.2.2 Visualization of the NP Morphology by Scanning Electron Microscopy 
The principle of the SEM has been described in chapter 5.2.4. Here the focus is on the 
working conditions used for the visualization of GNPs in PLGA. Therefore, a drop of the 
NP-suspension was distributed on a cleaned silica wafer. After approximately one minute 
of incubation, the remaining liquid was removed by a lint-free cloth. The sample was 
dried at room temperature and subsequently sputter coated to avoid charging effects. 
For sputter coating and SEM two different devices have been used. Which of the both set-
ups was used is indicated for each picture shown in this work. For the first set-up, the 
samples have been sputter coated with platinum (Edwards S150) and imaged with 5.0 kV 
by the lower secondary electron image (LEI) detector in a JEOL JSM-7500F scanning 
electron microscope. These experiments have been performed at the Structure & 
Technology Research Laboratory (Marburg, Germany). A second device was used for this 
work which is placed at the Helmholtz Institute for Pharmaceutical Research Saarland 
(HIPS, Saarbrücken, Germany). A 10 nm gold layer was sputtered in a Quorum Q150R ES 
sputter coater to prepare samples for imaging in an EVO HD15 SEM using an acceleration 
voltage of 5.0 kV and the secondary electron image (SEI) detector.  
6.2.2.3 Atomic Force Microscopy for Visualization 
For the visualization of GNPs in PLGA a JPK NanoWizard® I was used. Samples have been 
prepared on freshly cleaved mica surfaces. Therefore, 50 to 100 µl of the sample have 
been dropped on the surface to enable NPs to adhere. The remaining sample was 
removed with a lint-free tissue after 1 min of incubation time. Samples have been imaged 
in the intermittent contact mode in air using OMCL-AC160TS cantilevers (reflex side 
aluminum coated) with a resonance frequency of 300 kHz and a nominal spring constant 
of 26 N/m having tetrahedral tips with a final tip radius of 7 nm. Images have been 
processed with the JPK-SPM Data Processing Program. 
6.2.2.4 Gelatin Load and Release from GNPs in PLGA 
GNPs in PLGA have been tested for gelatin in regard of entrapment efficiency, load and 
release via bicinchoninic acid assay (BCA assay). The use of the QuantiProTM BCA Assay Kit 
allowed protein detection in a linear fashion from 0.5 to 30 µg/ml. The working principle 
is the formation of Cu2+-protein complexes at alkaline conditions, which leads to a 
reduction of Cu2+ to Cu1+ in a proportional amount to the protein concentration. BCA then 
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forms a purple-blue complex with Cu1+ in basic conditions, which can be read out by 
absorption at a wavelength of 562 nm.176 The structural formula of the formed complex is 
illustrated in Figure 6-2 
 
Figure 6-2: Reduction of copper II to copper I by proteins and formation of a complex with bicinchoninic acid under 
alkaline conditions 
To determine the efficiency of the GNP embedment 10 mg freeze-dried NPs have been 
dispersed in 1 ml NaOH (0.5 M) to dissolve PLGA at 37°C for 90 min. After this time, a 
clear solution was obtained and the pH was adjusted to pH 7. The volume was filled up to 
10 ml and 150 µl samples have been pipetted to a 96 well plate in triplicate and mixed 
with an equal amount of BCA reagent. The plates have been incubated for 2 h at 37°C and 
measured at 562 nm with the Infinite®M200 plate reader. Calibration curves have been 
prepared with different gelatin concentrations; as blank PLGA NPs have been used. Both 
gelatin and PLGA NPs underwent the same treatment as GNPs in PLGA samples. The 
entrapment efficiency was calculated by the following formula:  
Entrapment Efficiency (%) =
Mass Gelatin in NPs(g) / Mass NPs (g) 
Mass Gelatin used (g) / Mass Polymer used (g)
∗ 100  (6) 
For the calculation of the relative amount of gelatin in the formulation the equation 
below was used:  
𝐿𝑜𝑎𝑑(%) =
Mass Gelatin (g)
Mass Nanoparticles (g)
∗ 100       (7) 
To evaluate the stabilization efficacy the gelatin release was tested. Therefore, GNPs in 
PLGA have been freeze dried with dissolved sorbitol to ensure complete redispersibility 
afterwards. 10 mg NPs have been dispersed in 10 ml PBS-Buffer (pH 7.4) and divided in 
1 ml aliquots. Samples have been incubated at 37°C for different durations until 
examination of released gelatin mass. Afterwards, samples were centrifuged at 20,000 g 
for 15 min at 15°C. 900 µl supernatant was collected and investigated in triplicates of 
150 µl mixed with 150 µl of BCA reagent as described above. 
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6.2.2.5 Influence of Solvent, Nonsolvent and Stabilizer 
To obtain a suitable carrier system gelatin should be encapsulated in the highest possible 
amount. At the same time a sufficient stabilization of gelatin by the PLGA-coating is 
needed, resulting in sustained release of gelatin from the particles. Briefly, the production 
scheme was as described hereafter: Gelatin was dissolved and precipitated in an 
antisolvent. Subsequently, the so obtained GNPs were mixed with a PLGA solution. This 
nanodispersion was then emulsified in an aqueous PVA solution. To obtain GNPs coated 
and stabilized in PLGA the organic solvents were removed by solvent evaporation. 
Different antisolvents, solvents and stabilizers have been tested on their influence to the 
obtained NPs characteristics. The range of solvents tested was limited through the 
requirements they underlie. The demands are illustrated in Figure 6-3.  
 
Figure 6-3: Demands on the solvents to their behavior towards gelatin, stabilizers, PLGA and to each other 
The solvent of the gelatin (solvent 1) has to be miscible with the antisolvent (solvent 2). 
Therefore DMSO and water, inclusively their mixtures in different ratios have been 
chosen to dissolve gelatin at 50°C. For the nanoprecipitation, acetone and DMF have been 
the antisolvents of choice. The further requirements for the antisolvent are on one hand 
the possibility to dissolve a stabilizer for the freshly prepared GNPs and on the other hand 
the miscibility with the solvent of the PLGA phase (solvent 3), which has to be an 
antisolvent for gelatin itself, and thus was chosen to be ethyl acetate. The last step is the 
formation of an emulsion, which brings the last requirement for the solvent used to 
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dissolve PLGA as it must not be miscible with the outer phase (solvent 4) which is a 2 % 
(w/V) PVA solution in water. As stabilizer two substances have been tested. The first was 
dodecylamine (DDA) which was chosen because of the relative small size. The other 
tested compound was poloxamer 188. The block-co-polymer was chosen as it was shown 
to have, in comparison to other additives, the best results in regard to the encapsulation 
and release of proteins into PLGA.177 The experiments have been evaluated in terms of 
hydrodynamic diameter, zeta-potential, encapsulations efficacy, load and release of 
gelatin by BCA assay and visualized with SEM and SPM. 
6.2.2.6 Standard Formulation 
After testing the influence of solvent, nonsolvent and stabilizer a standard formulation 
was set. 40 mg gelatin B derived from bovine animals was melted in 40 µl deionized water 
at 50°C and subsequently dissolved in 1 ml DMSO under continuous stirring at 50°C. 
260 µl gelatin solution was precipitated dropwise in 1.5 ml of a 1:1 mixture of acetone 
and DMF, containing 6.67 % [w/V] poloxamer 188 as stabilizer at 750 rpm.  
 
Figure 6-4: Production scheme of GNPs in PLGA. Gelatin is dissolved and subsequently precipitated in a stabilizer 
containing antisolvent. The obtained NPs are mixed with a PLGA solution. This mixture is then emulsified in a 2 % 
aqueous PVA solution. If drugs are incorporated, they have been co-precipitated  
The freshly prepared NP dispersion is transferred to 5 ml of an ethyl acetate solution with 
50 mg dissolved PLGA. This dispersion is slowly dropped in a 2 % aqueous solution to form 
an emulsion with the inner phase consisting of gelatin nanoparticles surrounded by PLGA. 
The emulsion was homogenized by an UltraTurrax® T25 using the S 25 N – 8 G disperser 
tool at 12,000 rpm for 5 min. The production is illustrated in Figure 6-4. Vials are filled up 
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with water and stirred over night with open lid for solvent evaporation and finally GNPs in 
PLGA have been purified by centrifugation three times at 10,000 g for 15 min at 15°C. 
6.2.2.7 Varying the Gelatin to PLGA Ratio 
To enhance the hydrophilic fraction, and thus provide a higher proportion for the 
encapsulation of hydrophilic drugs, it is of high interest to vary the ratio of gelatin to PLGA 
during the NP production. In the standard procedure 10 mg gelatin were used with 50 mg 
PLGA. This means a ratio of 1:5. Compositions are varied to 1:1.25 and 1:0.625. The rest 
of the protocol was kept constant to the standard procedure described in 6.2.2.6. To 
examine the particle formation, the morphology was tested by SEM and SPM. 
Furthermore, hydrodynamic diameter, PdI and zeta potential have been determined. To 
test the efficiency of GNP entrapment and stabilization the load and release of gelatin 
was determined by BCA assay as described in chapter 6.2.2.4. 
6.2.2.8 Gelatin A Nanoparticles in PLGA 
The chemical characteristics of gelatin A and B are slightly different. Here, the attention is 
on the different IEPs of the two types of gelatin. For gelatin type B, used for the standard 
formulation, it is between pH 4.7 to 5.9 and for gelatin A between 6.0 and 9.5.58 This 
results in different zeta potentials at the same pH. NPs made from gelatin A show a 
positive zeta potential at neutral pH. This should modify the interaction between the 
freshly produced GNPs with the PLGA. To address this, GNPs in PLGA have been produced 
according to the standard procedure described in chapter 6.2.2.6 with the following 
differences. Gelatin B was replaced by gelatin A (Bloom 175, Mw 40,000 – 50,000Da). In 
addition, the used amount of gelatin was varied to 10 mg, 20 mg and 30 mg respectively. 
All formulations have been investigated with and without poloxamer 188 in the 
nonsolvent phase as triplicates. Particle morphology was examined in SEM. Zeta potential 
and hydrodynamic diameters have been measured by DLS and gelatin load was analyzed 
by BCA assay. 
 Cell Viability Assay 
The toxic potential of new formulations is usually firstly examined in vitro with cell 
viability tests to gain insights in the biocompatibility. As only materials are included in the 
formulation whose biocompatibility is already proven and which are already in use for 
parenteral applications a very low toxic potential was expected. The cell work in this 
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section was performed in collaboration with Thorben Fischer within his Diploma thesis. 
Cell viability was investigated with a MTT assay on adenocarcinoma human alveolar basal 
epithelium cells A549. The MTT assay displays a rapid and precise method to quantify 
viable cells. The principle is a reductive ring opening, in mitochondria of living cells, from 
the yellow 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to the 
dark blue formazan and measured at a wavelength of 550 nm.178 The reaction is 
illustrated in Figure 6-5. 
 
Figure 6-5: Reaction of the tetrazolium salt MTT to formazan during the cell viability test 
A549 cells have been chosen in regard of a possible further use of the NPs to develop a 
nano-structured microparticulate drug delivery system for pulmonary application. A549 
cells are widely used to mimic drug metabolism and interactions with drug delivery 
systems of type II pulmonary epithelial cells in vitro.179 A549 have been cultivated in 
RPMI-1640 with 2 mM glutamine and 10 % FCS in sterile 96-well plates until a cell number 
of approximately 10,000 cells per well. Cells have been washed with HBSS buffer two 
times and incubated with different concentrations of GNPs in PLGA for 4 h. For the 
evaluation, a positive and a negative control have to be included in the experiment. For a 
positive control the cells are treated with 2 % Triton X-100 which causes cell lysis due to 
the surface activity. HBSS was taken as positive control, to keep the cells in not harmful 
condition, so no induced cell death will occur during the incubation time. Before the cells 
have been incubated with 200 µl of MTT reagent for 4 h at 37°C they have been washed 
with HBSS buffer again. After the incubation time allowing for uptake of the tetrazolium 
salt and reduction to formazan the supernatant was removed. The formed formazan in 
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the metabolic active cells was then dissolved in DMSO for a quantitative read out at a 
wavelength of 550 nm with an Infinite®M200 plate reader. Positive and negative controls 
have been used to calculate the cell viability 
Cell viability (%) =
absorption sample−absorption positive control 
absorption negative control−absorption positive control
∗ 100  (8) 
All samples have been tested from three separately produced batches in triplicate. 
 Loading of Drugs 
This NP formulation was developed as a delivery platform for the use of different 
hydrophilic macromolecular drugs. Therefore, we investigated the load of compounds 
with different sizes and chemical characteristics. In the present thesis the loading 
processes and read outs for three of the examined compounds are described. The 
entrapment efficiency was calculated with the following equation: 
Entrapment Efficiency (%) =
Mass Drug in NPs(g) / Mass NPs (g) 
Mass Drug used (g) / Mass Polymer used (g)
∗ 100  (9) 
If the load in percent was examined it was calculated as follows 
𝐿𝑜𝑎𝑑(%) =
Mass Drug (g)
Mass Nanoparticles (g)
∗ 100      
 (10) 
6.2.4.1 Loading of Locked Nucleic Acid 
Locked nucleic acids are nucleic acid analogs with a 2´-O,4´-C-methylene bridge stabilizing 
the furanose in the C3´-endo conformation which is illustrated in Figure 6-6. LNA 
monomers can be coupled with other DNA or RNA monomers or phosphodiester linkers. 
The modification leads to an extraordinary binding affinity to the complementary strain. 
This holds true for fully modified strains as well as for mixmers (a combined oligomer of 
alternating short segments of LNA and DNA or RNA). The increased stability of LNA*DNA 
or LNA*RNA in comparison to the natural duplexes results in a raised thermal stability of 
4.0 to 9.3°C per induced LNA monomer. The modification results in a resistance to 
nucleases, which is an important aspect with respect to the use of LNA as therapeutic in 
vivo or diagnostic tool in vitro as nucleases are ubiquitous and so challenge nucleic acid 
therapeutics for example in serum samples or the target cells.180 The combination of 
these LNA characteristics lead to a prolonged half-life time in vivo which is reported to be 
up to 1 week in mice and 2 to 3 weeks in monkeys in comparison to free plasmid DNA 
which shows half-times of a few minutes.181 In vivo studies demonstrated a good 
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tolerance with less immuno-stimulation and acute toxicity, like complement activation or 
prolonged bleeding time, than nucleic analogs of earlier generations. After i.v. 
administration LNA accumulates in kidney, liver, bone marrow, spleens and lymph nodes, 
but does not reach brain, spinal cord, testis and lenses. LNA antisense strains are 
developed for example for the treatment in cancer, metabolic disorders or infectious 
diseases with ongoing clinical trials in different phases.182 The ability of LNA to cross 
cellular membranes is very low. This justifies the need of a biocompatible delivery system 
for LNA. Therefore, there are studies with complexes of LNA with polyethylenimine (PEI) 
which is a common positively charged complexing agent for transfection studies of 
nucleic acids.183 PEI is showing good transfection efficiencies but is related to toxic effects 
too.184 Therefore in this study the ability to load LNA into GNPs in PLGA as a potential 
non-viral vector is investigated.  
 
Figure 6-6: Structure of LNA in the β-D-ribo configuration 
GNPs in PLGAs have been produced according to the standard procedure described in 
6.2.2.6. For quantification LNA was labeled radioactive with phosphorus-32 (32P) which 
decays into sulfur-32 by β--decay (Figure 6-7).  
 
Figure 6-7: Decay of 32P into 32S by β—decay 
LNA was kindly provided by the Gruenweller lab at the department of Pharmaceutical 
Chemistry at the Philipps University of Marburg. Labelling was done by Dr. Kerstin 
Gruenweller-Lange from the same working group. For particle preparation 10 mg of 
dissolved gelatin was mixed with the necessary amount of labelled LNA to obtain 20,000, 
100,000 and 250,000 counts per minute (cpm) respectively. Gelatin was then precipitated 
together with LNA to obtain loaded GNPs in PLGA. After purification on the next day all 
samples have been divided and freeze dried and the gravimetric yield determined in 
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triplicate. Therefore, Eppendorf tubes have been weighted empty and after freeze drying 
with an analytical balance. In addition, the cpm of these samples were measured. This 
was used to calculate the entrapment efficiency of LNA with equation (9). For protection, 
all work was carried out behind an acrylic glass shield. NPs loaded with unlabeled LNA 
were used to measure hydrodynamic diameters and particle size distribution in the 
Zetasizer and morphology in SPM and SEM. 
6.2.4.2 Loading and Transfection with eGFP PEI,  
The cell work described in the following chapter was performed by Dr. Nadine Wilhelm at 
the Fraunhofer Institute for Biomedical Engineering (IBMT, Sulzbach/Saar, Germany and 
at the external side in Oxford, United Kingdom). 
The read out for this particle formulation was the expression of enhanced green 
fluorescent protein (eGFP) after the transfection of human embryonic kidney cells 
(HEK293T). This is a cell line which was derived in the late 1970s by the transfection of 
human embryonic kidney cells with DNA fragments of the adenovirus type 5.185 The 
plasmid for the expression of eGFP was isolated from Max Jacobs and Nadine Wilhem at 
the Fraunhofer IBMT (Sulzbach/Saar, Germany). The extraction followed the protocol of 
the used EndoFree Plasmid Mega Kit (no.: 12381). For the transfection studies sterile 
particles have been produced. Therefore, all vessels and devices, which were in contact 
with the formulation, have been autoclaved in a FVS/2 autoclave before use. Gelatin was 
autoclaved in a concentration of 40 mg/ml too. The production was performed in a 
laminar airflow workbench (Technoflow 2F120-II GS). Immediately before particle 
production 200 µl of a 1.5 mg/ml plasmid solution was mixed with 250 µl of gelatin 
solution. After NP assembly and purification according the normal protocol described in 
chapter 6.2.2.6. 2.5 ml of the NP suspension were dispersed in 10 ml of a 2 % (w/V) PEI in 
water solution and incubated for 15 min. PEI coated samples have been purified twice in 
the centrifuge at 6,000 g for 10 min. To be able to redisperse the particles after freeze 
drying, NPs have been collected in a freshly sterile filtered D-sorbitol solution after 
centrifugation and subsequently lyophilized in an Alpha 2-4 LSC freeze dryer. Preliminary 
transfection experiments with uncoated and positively PEI coated NPs, showed the 
predominance of the positively charged particles. Therefore, in the experiment with the 
sterile particles only this formulation was used. After freeze drying a part of the 
formulation was tested for sterility. For this test NPs have been incubated on agar plates 
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for 5 days at 37°C as well as autoclaved gelatin solution and a negative and a positive 
control. Afterwards the agar plates have been investigated for bacterial growth. Sterile 
particles have been redispersed in Dulbecco´s Modified Eagle Medium (DMEM). The 
transfection was started 24 h after cells are seeded and medium was refreshed to DMEM 
24 h after transfection. Images for evaluation have been taken 48 h after medium change 
at a wavelength of 543 nm. As control, cells have been grown without treatment and 
have been transfected with pure plasmid. 
6.2.4.3 Fluorescein-labelled Dextran 
Both already described tested substances are relatively small. As the objective of this 
thesis was to develop a platform system, which can be loaded with various drugs of an as 
large as possible size range, there is a need to investigate larger substances too. 
Therefore, fluoresceinisothiocyanat-labelled dextrans (FITC-dextran) with different 
molecular weights (20 kDa, 70 kDa, 150 kDa) have been encapsulated. Loading dose was 
1 mg per batch, which was added from stock solutions to the gelatin before precipitation. 
The following procedure was as described in 6.2.2.6. The read out was the loading and 
the encapsulation efficiency based on the fluorescence signals. Both were determined 
after particle hydrolysis in 0.5 ml NaOH (0.5 M) to dissolve PLGA at 37°C for 90 min and 
neutralization to pH 7 with 0.5 M HCl. Samples have been filled up with deionized water 
to 1 ml and measured in triplicate at a wavelength λ = 520 nm in 96-well plates with an 
Infinite®M200 plate reader. 
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 Further Analytics for Structure Analysis 
For smaller molecules good encapsulation efficiencies could be achieved, nevertheless 
the load was always relatively small and did not exceed 0.11 µg FITC-dextran70/mg NPs. 
This, together with a general interest in the exact particle structure, was the driving force 
to investigate in the exact particle structure. Three possible inner structures of polymer 
distribution are postulated which are illustrated in Figure 6-8. The optimal distribution of 
gelatin and PLGA would be one gelatin NP stabilized by a surrounding PLGA layer (a)). In 
b) the possibility of small GNPs embedded in a PLGA matrix is shown whereas c) 
represents the possibility of a hybrid particle where gelatin and PLGA are meshing over 
the entire particle. 
 
Figure 6-8: The three possible structures postulated for the standard formulation. The white part with blue lines 
indicates gelatin, the solid blue area represents PLGA. 
6.2.5.1 Confocal Laser Scanning Microscopy for Structure Analysis 
The first analysis regarding the structure was performed to investigate in the 
colocalization of gelatin and PLGA. Therefore, both polymers have been colored and 
examined in the confocal microscope. The working principle of CLSM is already explained 
in 5.2.6 for the interaction between cGNPs and A549 cells. In contrast to these 
experiments the following work was performed at a Zeiss Axiovert 100M. For the NP 
production the standard procedure described in 6.2.2.6 was adopted to have fluorescent 
dyes which can be detected separately from each other in both polymers. Therefore 
250 µl of the dissolved gelatin was mixed with 20 µl of a 50 mg/ml tetramethyl-
rhodamine isothiocyanate dextran 70 kDa (TRITC-dextran70) and precipitated in the 
acetone/DMF solution. TRITC-dextran loaded GNPs have been dispersed in fluorescein 
amine labelled PLGA (FA-PLGA), produced by Dr. René Rietscher according to literature186. 
As a reference pure FA-PLGA NPs and TRITC-dextran loaded GNPs in unlabeled PLGA have 
been used. For CLSM analysis particles have been diluted 1:10 and 920 µl NP dispersion 
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was incorporated in 80 µg of an agarose gel. For visualization an argon laser with a 
wavelength of 488 nm and a helium-neon laser with a wavelength of 543 nm respectively 
have been used.  
6.2.5.2 Transmission Electron Microscopy 
Transmission electron microscopy makes use of electrons penetrating through the 
specimen. Electron sources are usually LaB6 rods or tungsten filaments. The acceleration 
voltage ranges from 60 keV to 3 MeV. The electron beam generation is the same as 
described for SEM in chapter 5.2.4. For imaging very thin samples are necessary. The 
electron beam is bundled before hitting the sample so electrons are imping in parallel to 
each other. On the way through the specimen the electron beam interacts with the 
sample. When the beam encounters an atom it is scattered, if no atoms are encountered 
it goes straight through the sample. The scattering is dependent on the atom´s electron 
density and the specimen thickness. An aperture filters electrons which are scattered to a 
greater value. As scattered electrons are removed from the beam, areas of higher 
electron scattering occur dark, whereas bright areas are regions without or with only low 
scattering. This imaging mode is called bright field (BF).  
 
Figure 6-9: Scattering possibilities of electrons after interacting with the specimen 
If the aperture is moved to the side, unscattered electrons are removed and scattered 
electrons are detected we talk about dark field imaging. For amorphous substances no 
additional information can be received. Just the bright and dark areas are inverted. 
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Electron scattering is not only influenced by the atom density. Depending on where the 
beam encounters the atom the scattering has different characteristics. Figure 6-9 
illustrates the possibilities how electron scattering can occur. Elastically scattered 
electrons do not undergo any energy loss whereas inelastically scattered electrons lose 
energy. This loss is specific for the element the electron beam is in interaction with and 
the region of the atom where the electron beam is hitting the atom. Secondary electrons 
and back scattered electrons interact relatively close to the surface and are used in SEM. 
Electrons going through the specimen are scattered either elastically, without any energy 
loss, and used for imaging in TEM in the BF mode or inelastically, with an element specific 
energy loss, used in electron energy loss spectroscopy (EELS) and energy filtered TEM 
(EFTEM).187 
6.2.5.3 Cryo-TEM for Structure Analysis 
In cryo-TEM NPs can be imaged in their frozen-hydrated state and so can be depicted in 
the way they are present in suspension. Frozen samples are very beam sensitive. To 
prevent sample damage a low electron dose is required. For polymers which are not 
packed in a dense manner, the contrast can be relatively low. Nevertheless, it is possible 
to see differences in the electron density.188 These differences are supposed to 
distinguish between gelatin and PLGA. As reference systems, pure PLGA and pure gelatin 
NPs have been used as well as a mixture of the two formulations. For imaging 3 µl 
nanosuspension were dropped on a holey-carbon film on a copper grid and stamped for 
2 sec to the grid (Plano S147-4). Excessive water is removed during plotting. The specimen 
was immersed into -165°C cold liquid ethane, with a Gatan CP3 cryoplunger, to freeze it 
within a time as short as possible to obtain an amorphous state. Samples have been kept 
at liquid nitrogen and transferred to a Gatan 914 cryo-TEM holder. A JOEL JEM 2100 TEM 
with a LaB6-cathode and a Gatan Orius SC100 camera was used to image samples at a 
temperature of -170°C with an acceleration voltage of 200 kV in the bright field mode. 
The electron dose was set to 32 pA/cm². Images have been taken in a time series to 
capture the transformation process of the materials during the exposure to the electron 
beam. Particle diameter and shell thickness are measured with ImageJ. 
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6.2.5.4 Energy filtered TEM 
As described in 6.2.5.2 electrons scattered inelastically by the specimen undergo an 
energy loss. The scattered beam can be split in an electric prism according to the energy 
of the electrons. In this way, electrons with the same energy occur at the same area at so-
called energy selective levels. In EELS these levels are captured by a charge couple device 
(CCD) camera and the brightness can be read out. This is then displayed in an EEL 
spectrum. The “zero-loss-peak” is representing elastically scattered electrons and its 
maximum is set to “0” at the abscissa. The “zero-loss” area is followed by the low loss 
area which ranges from 0 eV to 100 eV. All energy losses above 100 eV occur when inner 
shell electrons are ionized. In this area the intensity is very low, therefore the aperture 
has to be enlarged and the measurement time needs to be prolonged. To avoid damage 
to the camera the zero-loss-peak and the low-loss-area are usually cut off. In the core-loss 
area the energy is, in contrast to the low loss area, not only specific for the element they 
are also specific for the orbital the ionized electron was located in before ionization. The 
EEL-spectra shown in this thesis are representing the core-loss area. An example for the 
core-loss region of an EEL spectrum for crosslinked GNPs is shown in Figure 6-10.  
 
Figure 6-10: Core-loss area of an electron energy loss spectrum of crosslinked gelatin nanoparticles showing the carbon 
and nitrogen edges. 
Images generated in the energy filtered TEM mode make use of the energy loss of 
inelastically scattered electrons. After passing the specimen, scattered electrons need to 
be focused to bring them in the same angle in the electronic prism, where the electrons 
                                                                  Stabilizing Gelatin Nanoparticles without Crosslinking 
63 
are separated according to their energy. In front of the detector a filtering slit is placed 
that allows only electrons of certain energy to pass and subsequently be imaged element 
specific. To eliminate the background signal at least two pictures are taken, one directly 
before the edge of the element of interest and the other one at, or immediately after, the 
edge. The resulting image shows exactly if the corresponding element is present at a 
certain place or not. By comparing different images, the material composition and in this 
experiment the polymer, whether it contains nitrogen, which indicates gelatin or carbon 
or oxygen, which are present in both polymers. For EFTEM analysis 3 µl of the 
nanosuspension was dropped on a holey-carbon film and, after complete drying at room 
temperature, transferred to a JOEL JEM 2100 TEM. At an acceleration voltage of 200 kV 
energy filtered images of the elements carbon, nitrogen and oxygen have been taken with 
a Gatan image filter (GIF 2002) and a 2048x2048 pixel slow-scan camera (Gatan model 
850). As reference system pure gelatin particles have been investigated. 
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6.3 Results and Discussion 
 Formulation Development of GNPs in PLGA 
The aim of the experiments described in this chapter was a core-shell formulation of 
GNPs stabilized by PLGA without crosslinking to be used as formulation platform for the 
delivery of hydrophilic macromolecular APIs. Therefore, the hydrophilic gelatin part 
should show a constant and sustained release so the embedded drug will be available 
over a prolonged time range. In addition, the gelatin proportion should be as high as 
possible. 
6.3.1.1 Development of a Suitable Formulation  
The starting point of the formulation development was the study with GE100-NiNOS, 
which are GNPs stabilized with Eudragit® E100.189 The first system proving the possibility 
to conserve the shape of GNPs without crosslinking. As Eudragit® E100 is not suitable for 
many applications the system needs to be developed further. Therefore, different 
combinations of solvents and stabilizers have been tested all meeting the requirements 
described in chapter 6.2.2.5. 
 
Figure 6-11: Hydrodynamic diameters and PdIs of GNPs in PLGA with DDA as stabilizer in dependency of the 
homogenization time a) one minute, b) three minutes and c) 5 minutes and the number of centrifugation steps for 
purification. 
The formulation of which the hydrodynamic diameters and PdIs are presented in Figure 
6-11 have been produced with DMSO to dissolve gelatin which was then precipitated in 
acetone:DMF 1:1 with DDA as stabilizer. PLGA was dissolved in ethyl acetate. The 
particles obtained show hydrodynamic diameters around 250 nm and a PdI between 0.15 
and 0.2 with a tendency to smaller sizes with a narrower particle size distribution. These 
parameters are well suitable for the formulation. Looking at the sizes and PdIs after 
already the first centrifugation step NPs size and PdI are rising even with a relative low 
centrifugation speed of 7,000 g indicating agglomeration. A homogenization time of 5 min 
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was chosen as NPs showed the smallest hydrodynamic diameter with a good PdI. Longer 
homogenization did not lead to smaller particles or PdIs. NPs showed a round shape and a 
smooth surface but have not been stable in SEM for imaging. The gelatin content was 
around 9.04 % with a high gelatin burst release of 28.02 %. In the following formulation 
development the improvement of these parameters was addressed. In a first step the 
influence of the nonsolvent was investigated. Acetone and DMF with DDA as stabilizer 
have the function of the nonsolvent solution. As can be seen in Table 6-1, the sizes were 
increased to hydrodynamic diameters of 309 nm and 418 nm with a good particle size 
distribution for acetone. The encapsulation efficiency and load of gelatin was decreasing 
for pure nonsolvents. This means a smaller hydrophilic compartment in the formulation. 
At the same time, the gelatin burst release increased. As the hydrophilic proportion 
should be increased for a potentially higher drug loading, the first formulation with 
acetone:DMF in an equal ratio was used as nonsolvent again. Now the stabilizer was 
changed to Pluronic®F68 as described in chapter 6.2.2.5. The sizes and PdIs have been still 
in the range aimed for and the ζ-potential was approximately -20 mV, which is a strong 
enough surface charge for a stable particle formulation. Looking at the gelatin 
entrapment the new formulation shows clear advantages over the former ones. Here an 
entrapment efficiency of 64.4 % could be achieved. The load of 12.02 % is still expandable 
but is improved in comparison to the former formulations. Looking at the release 
characteristics a burst release of less than 30 % can be detected. The further release 
characteristics are addressed later in this paragraph. To complete the study, Pluronic® 
F68 was as well tested with pure acetone as antisolvent. This formulation row shows the 
same tendency as when DDA was used for stabilization. Therefore, the combination of 
acetone and DMF together with poloxamer 188 was set as standard for further 
investigations.  
 
Table 6-1: Formulation development with different nonsolvents and stabilizers. Acetone and DMF in an equal mixture 
together with poloxamer 188 showed the best results in all tests and therefore was set as standard formulation. 
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This standard formulation shows perfectly spherical NPs in SEM and SPM investigations. 
The results of the visualization experiments are presented in Figure 6-12. Particle size 
determined in SEM, with a diameter of 135.75 ± 23.07 nm, is smaller than measured with 
DLS. This is according to the expectations and can be explained because in DLS the 
hydrodynamic diameter is determined which includes the surrounding solvation shell. As 
a second reason, particle shrinkage during drying has to be considered. 
 
Figure 6-12: Images of GNPs in PLGA standard formulation in SEM a) and displayed in a closer view in SPM height 2D 
image in b) with the belonging 3D height image in c) and a cross-section in d). The cut through the NPs for the cross 
section is marked in b). It shows the spherical particle shape with a diameter of around 175 nm and a height of 115 nm. 
The SPM height images and the cross-section presented in Figure 6-12 b)-d) have been 
taken in dry conditions and underline the particle shape and the smooth surface. Particles 
do not show any dents or holes. The selected particle shows a diameter of approximately 
175 nm with a height of 115 nm in the cross-section. Compared with cGNPs captured in 
air the new formulation shows a very slight collapse only. Release profiles and 
encapsulation efficiency was investigated by BCA assay. The gelatin release profiles of the 
three formulations with the most promising encapsulation efficacy and load of gelatin 
have been determined over 6 days. The result is presented in Figure 6-13. Both DDA-
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stabilized formulations showed a high burst release of 100 % and 60 % respectively. With 
acetone:DMF as nonsolvent (60 % burst release) after 6 days 10 % more are released in 
comparison to the start of the experiment. Acetone and DMF in equal proportions with 
poloxamer 188 for stabilization showed only a burst release of less than 30 %. Gelatin is 
released continuously over 6 days. After this period 60 % is released from the system, so 
40 % are still remaining and building the matrix for a sustained drug release. In 
combination with the determined physicochemical parameters this properties are well 
suited for a drug delivery platform system for the delivery of hydrophilic APIs and set as 
the standard formulation described in chapter 6.2.2.6. 
 
Figure 6-13: Gelatin release of GNPs in PLGA with different nonsolvents and stabilizer over 6 days. Gelatin content is 
determined by BCA assay. 
Based on the standard formulation, investigations, aiming for a simplified process, have 
been performed. The gelatin load and release should be at least the same compared to 
the standard formulation. Therefore, the preheating of gelatin in water was skipped and 
DMSO as solvent was mixed with water or completely replaced. In a second step gelatin 
was dissolved in water with adjusted pH values of pH 6, 4 and 3. The aim was to enhance 
the electrostatic interaction between negatively charged PLGA and positively charged 
gelatin at pH values lower than the IEP. All further investigations have been tested against 
the standard formulation. Size and particle size distribution of the resulting NP 
formulation are shown in Figure 6-14. Except of the equal mixture of DMSO and deionized 
water all hydrodynamic diameters range around 250 nm. 
Stabilizing Gelatin Nanoparticles without Crosslinking   
68 
 
Figure 6-14; Sizes and PdI of GNPs in PLGA prepared with different gelatin solvents. Most formulations showed a 
hydrodynamic diameters around 250 nm and a narrow particle size distribution with a PdI below 0.2.  
Regarding the proportion of the gelatin compartment no benefit could be achieved. In the 
opposite, the gelatin load decreased. The highest loading was 2.7 % when gelatin was 
dissolved with deionized water and an adjusted pH of 4. This was slightly better than pH 6 
(gelatin load of 2.05 %) what supports the hypothesis that the oppositely charged gelatin 
shows more interaction with PLGA. Nevertheless, the best results could be achieved 
when gelatin was dissolved in DMSO. As no benefits where obtained, the solvent 
combination was kept as in the standard formulation. 
6.3.1.2 Varying the Gelatin to PLGA Ratio 
An enhanced hydrophilic reservoir for the encapsulation of a high amount of drug was, as 
mentioned, the aim of this study. Therefore, the ratio of the raw materials was changed 
to a higher amount of gelatin than in the standard formulation. The evaluation included 
hydrodynamic diameter, PdI, ζ-potential, gelatin load, entrapment and release. Results 
are summarized in Table 6-2. Hydrodynamic diameters, PdI and ζ-potential stay nearly the 
same for all variations. The same holds true for the entrapment efficiency, which ranges 
from 63 to 71 %. In contrast, the gelatin load increased with the increasing proportion of 
gelatin used and reaches a share of nearly 45 % in the formulation with the highest used 
gelatin amount. Gelatin showed a relative high burst release of 45 % and 57 % 
respectively after half an hour. After one hour 54 % of the gelatin from the formulation 
                                                                  Stabilizing Gelatin Nanoparticles without Crosslinking 
69 
made by a ratio of 1:1.25 is released and 65 % of the ratio 1:0.625. As the delivery system 
is based on gelatin this means after one hour only 46 % or 35 % respectively of the 
hydrophilic compartment is left. For the standard formulation was still around 70 % 
gelatin left after the same time. 
 
Table 6-2: Different gelatin to PLGA ratios and the respective NP characteristics  
 
Figure 6-15: SEM image of particles made by a gelatin to PLGA ratio of 1:1.25 in a) and 1:0.625 in b). 
 
Figure 6-15 it can be seen, that particles keep their morphology with the raising gelatin 
fraction. NPs are still roundly shaped with a smooth surface and show a homogeneous 
particle size distribution in both formulations. This supports the values in Table 6-2. It can 
be summarized that the gelatin proportion can be enhanced with changing the ratio of 
raw materials while keeping the evaluated physicochemical parameters consistent. The 
release profile does not provide a sustained release, but could be enough for further 
processing like PEI coating for gen delivery like the delivery of plasmids where 
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transfection studies are performed with PEI coated GNPs in PLGA particles (see chapter 
6.2.4.2). 
6.3.1.3 Comparison between Gelatin A and Gelatin B 
Gelatin A NPs exhibit a positive surface charge at neutral pH, which can be explained by 
the IEP at a pH between 8.0 and 9.0. This means an opposite charge of gelatin and PLGA. 
Based on the results from chapter 6.3.1.1 the electrostatic interaction should be 
enhanced and thus the encapsulation of a higher gelatin amount with the same ratio of 
raw material should be possible. Particle sizes are presented in Figure 6-16 a). They are 
larger than particles prepared by gelatin B whereas the particle size distribution is 
approximately the same as for PLGA NPs. This can be due to different reasons such as 
differences in the molecular weight, in solubility or viscosity. Opposite to the other 
formulations gelatin A NPs in PLGA exhibit positive ζ-potentials. Due to the IEP of gelatin 
this might be feasible. However, as gelatin should be packed in PLGA or both polymers 
building a hybrid NP it was certainly not expected to obtain a positive surface charge as 
the positively charged gelatin groups have to be at the outside of the particle to achieve a 
positive ζ-potential.  
 
Figure 6-16: Gelatin A NPs in PLGA a) Hydrodynamic diameter and PdI and b) ζ-potential. Both parameters are compared 
to gelatin B NPs (Gelatin B) in PLGA and pure PLGA NPs. 
The hydrophilic proportion is slightly enlarged with a gelatin compartment of 
approximately 15 %. Release studies have not been performed as the positive ζ-potentials 
indicated differences to the standard system. Nevertheless, gelatin A has to be 
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considered for a further formulation development especially in regard of intra cellular 
delivery such as for nonviral gene transfer. Here a positive surface charge is advantageous 
and furthermore, positively charged nanosystems show higher transfection rates than 
their negatively charged counterparts. Therefore particles are often coated with PEI, 
which brings a, not only charge dependent, cytotoxicity into the formulation.190 The good 
in vitro safety profile of gelatin A NPs could be already shown in literature.191 
Furthermore, a larger in vitro uptake could be demonstrated for cationic gelatin A NPs in 
comparison to negatively charged GNPs produced by gelatin B.192 This could be a 
potential application for the GNP in PLGA prepared with gelatin A and an advantage of 
gelatin as biopolymer coming with different characteristics, which can expand the spectra 
of the formulation platform. 
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 Cell Viability Assay 
The toxicity of NP formulations is a very important parameter to investigate during 
formulation development. Here for first insights in vitro cell viability was tested with a 
MTT assay. As a control system, with known good cell viability, PLGA NPs were used. The 
test results showed a very good tolerance of both NP formulations tested with A549 cells 
after 4 h. Concentrations from 70 µg/ml to 0.9 mg/ml have been investigated. Values 
above 80 % cell viability are considered as nontoxic. This is indicated in Figure 6-17 with a 
green background. Even in high concentrations both formulations are very well tolerated. 
Whereas the percentage cell viability stays constant for PLGA NPs, cell viability was 
increasing with decreased GNPs in PLGA concentration. This indicates an advantage of the 
composite particles over pure PLGA at concentrations lower the 280 µg/ml.  
 
Figure 6-17: Cell viability after 4 h incubation on A549 cells tested by MTT assay. All tested concentrations are in the as 
nontoxic considered range.  
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 Loading of Drugs 
6.3.3.1 Loading of Locked Nucleic Acid 
GNPs in PLGA have been loaded with radioactive labeled LNA in three concentrations 
20 kcpm, 100 kcpm and 200 kcpm. LNA loaded particles have been investigated for 
morphology in SEM and SPM. The smooth surface of the round shape of 20 kcpm loaded 
NPs are visualized in Figure 6-18.  
 
Figure 6-18: Morphology of LNA loaded GNPs in PLGA in SEM (a) and in an SPM height image (b). 
Due to safety reasons, radioactive labelled samples could not be measured in the 
zetasizer. Two non-radioactive formulations with LNA amounts equivalent to the samples 
with 20 kcpm and 100 kcpm have been used to evaluate hydrodynamic diameters. The 
size of loaded NPs was around 225 nm and therefore, approximately 50 nm smaller than 
pure GNPs in PLGA. In comparison to control NPs, PdIs are slightly decreased too. With 
0.139 and 0.118 particles show a narrow size distribution. Hydrodynamic diameters and 
PdIs are summarized in Figure 6-19 b).  
 
Figure 6-19: a) Encapsulation efficiency of radioactive labelled LNA in GNPs in PLGA in different LNA concentrations and 
b) hydrodynamic diameters and PdI´s of LNA loaded NP formulations.  
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The encapsulation efficiency, which is shown in Figure 6-19 a), was evaluated according to 
equation (9). The encapsulation efficiency of all tested concentrations was over 100 % 
and showed no significant difference (significance tested with Student’s t-test, p > 0.05). 
Values above 100 % are possible due to the equation, which includes the ratio from drug 
to polymer used for the production. If, compared to the polymer, a higher percentage of 
drug goes to the end formulation the encapsulation efficiency increases. In this case the 
highly hydrophilic LNA goes to a very high percentage to the gelatin particles in the NP 
formulation. The smooth particle morphology with particle sizes of 225 nm and the very 
good encapsulation efficiency show the high potential of the formulation for intracellular 
delivery in gene therapy.  
6.3.3.2 Loading and Transfection with eGFP 
In cooperation with the IBMT the transfection of plasmid-loaded GNPs in PLGA was 
tested. The particle system not only protects the plasmid from degradation. In addition, it 
functions as a nonviral vector system for the delivery into the cell. For a successful 
transfection study the absence of microbes needs to be ensured. Microbes would 
contaminate cells and therefore could change their behavior and thus falsify the 
transfection study. As preliminary tests showed contamination in the particle 
formulation, the production was changed to aseptic conditions (6.2.4.2).  
 
Figure 6-20: Sterility test on agar plates after 120 h of incubation at 37°C a) GNPs in PLGA before freeze drying, b) GNPs 
in PLGA after freeze drying with sorbitol as cryoprotector and c) a positive control with a contaminated solution. 
To prove the absence of bacteria after all production steps, including freeze drying, the 
formulation was incubated on agar plates and compared with a contaminated positive 
control and a negative control which was a blank agar plate. Agar plates incubated with 
plasmid-loaded GNPs in PLGA before and after freeze drying are shown in Figure 6-20 a) 
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and b) as well as the positive control in Figure 6-20 c). After the successful aseptic particle 
formation the plasmid-loaded particles have been used for transfection of HEK293T cells 
with the plasmid coding for eGFP. Green fluorescent protein is a popular readout for 
transfection studies.  
 
Figure 6-21: Transfection of HEK293T cells with eGFP as well as two controls each consisting of a light microscope and a 
fluorescent image. Cells without treatment in a) and cells incubated with plasmid without a vector in b). The successful 
transfection displayed in c) was performed with plasmid-loaded GNPs in PLGA. Scale bars represent 200 µm 
As control untreated cells and cells which are only transfected with the blank plasmid 
were used. Both did not show any green fluorescence. As can be seen in Figure 6-21 cells 
transfected with the plasmid-loaded PEI layered GNPs in PLGA displayed in c, exhibited 
green fluorescence. This proves the encapsulation of the plasmid in the particle system as 
well as the potential of the new formulation platform for the use in intracellular drug 
delivery. Transfection was studied in two separately produced batches, with the 
restriction that the batch of the first test introduced contamination to the cells. The 
transfection rate is lower in the aseptic produced batch shown here and could be 
enhanced with a further improved formulation. Possible modifications could be an 
increased plasmid load to ensure all NPs can act as carrier system and thus transfect the 
cell after internalization. Another important parameter for the successful delivery of the 
drug is the release after internalization. As liberation was not studied here it can be that 
either some particles already released the loaded plasmid before they reach the 
cytoplasm or the release and exhibition of eGFP in the cell is not completed in the time 
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used in this study. Therefore, the release could be evaluated in different media mimicking 
the conditions in different cell compartments. Nevertheless, for a first insight in the use of 
the new platform in intracellular transfection the results are promising and should be 
further investigated in upcoming studies. 
6.3.3.3 Fluorescein-labelled Dextran 
A model compound to mimic the drug load was planned to encapsulate. Requirements, 
which had to be met, have been an easy analytical set up to detect and quantify the 
loading and the simple possibility to change the molecular weight. Therefore, the 
compound of choice was FITC-dextran. After the production procedure and freeze drying 
the particles they have been analyzed for load and entrapment efficiency. An entrapment 
efficiency of only 0.659 % for FITC-dextran70 could be calculated. With an efficiency of 
0.59 % for FITC-dextran70 in PLGA no real difference could be detected. This is in contrast 
with the expectations as gelatin should encapsulate the hydrophilic FITC-dextran70 to a 
significant higher extent than PLGA. The same result is achieved regarding to the load 
which was around 0.11µg per mg NP formulation no matter if FITC-dextran70 was 
encapsulated in GNPs in PLGA or pure PLGA NPs. The low loading can have different 
reasons at one hand the drug could already be diffused out during the solvent 
evaporation step or while cleaning the NPs and on the other hand it could be because of 
the relative low hydrophilic compartment which only covers 12.5 % of the whole system. 
After the promising results of the encapsulation of LNA and the transfection studies 
described above this low loading was not expected. In addition, a delivery system, 
capable to load a high amount of hydrophilic macromolecules, was aimed for. Therefore, 
these results were not satisfying. As the gelatin content of the current formulation is only 
around 12 %, the inner structure of the system should be exactly known, before more 
time and resources are invested for an enhanced loading. Therefore, the FITC-dextran 
experiments were stopped at this point and the further research concentrated on the 
investigation of the exact structure. 
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 Further Analytics for Structure Analysis 
The knowledge about the exact polymer distribution in the NP belongs to a complete 
characterization. The next chapter is about different methods for the investigation of the 
inner structure of the platform formulation for the delivery of hydrophilic 
macromolecules. The methods range from colocalization of polymers to show both, 
gelatin and PLGA, are actually forming the NPs to an element specific imaging in energy 
filtered TEM using nitrogen as differentiation between gelatin and the other materials. 
6.3.4.1 Confocal Structure Analysis  
The first method was about the colocalization of gelatin and PLGA. The polymers are 
colored with different fluorescent dyes and excited with lasers at the appropriate 
wavelengths. The hydrophilic gelatin was loaded with TRITC-dextran70 and PLGA was 
covalently coupled to fluoresceinamine. To enable the investigation in colocalization, 
particles are immobilized in an agarose gel. In Figure 6-22 the two channels are displayed 
separately in the top row and overlaid in the bottom row. The red channel shown in a) 
display the distribution of TRITC-dextran70 and the green channel in b) is representing FA-
PLGA. It is obvious that in areas with a green signal the TRITC-dextran70 can be detected 
too. In c) both channels are overlaid and show the colocalization of gelatin and PLGA by a 
slight change in color. With these experiments, it was possible to proof that the new 
formulation consists of both used polymers and they are perfectly colocalized. The exact 
distribution is not accessible by CLSM as the resolution is limited to approximately 
200 nm. Therefore, TEM analysis followed to gain more insights due to the higher 
resolution. 
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Figure 6-22: CLSM images of TRITC-dextran70 GNPs in FA-PLGA. A) TRITC-dextran70 in red, b) FA-PLGA in green and both 
channels overlaying in c). The images show a good colocalization between the two dyes. 
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6.3.4.2 Cryo-TEM for Structure Analysis 
To increase the resolution, NPs have been examined in cryo-TEM. Particles are imaged in 
a thin layer of polymorph ice. The formulation was examined in time intervals to 
investigate the alteration caused by the energy brought to the system during the 
measurement. NPs reaction to the energy was compared to pure PLGA particles and to 
crosslinked gelatin NPs as well as a mixture of both materials and to identify the behavior 
of the materials in the electron beam. 
 
Figure 6-23: a) to c) represent a mixture of cGNPs and PLGA NPs in a time series in cryo-TEM. Particles show different 
sensitivity to the electron beam and the degradation patterns vary between the populations. 
In Figure 6-23 a mix of PLGA NPs and cGNPs is imaged and observed over time of a few 
minutes in the electron beam. In a), which is the first image taken, all particles look 
similar with the difference that some of the particles have a higher contrast to the 
background than others and thus appear darker. In b) a fraction of the imaged particles is 
already degraded by the high energy whereas the other population is still intact. In c) all 
particles underwent a modification.  
 
Figure 6-24: Crosslinked gelatin NPs to the right immediately after focusing (a)) and after degradation (b)) and to the 
right (c) and d)) PLGA NPs showing fast degradation with the formation of large bubbles. Scale bars are representing 
0.5 µm. 
However, the disintegration pattern is rather different. The darker NPs from the first 
image show less resistance to the electron beam in addition the degradation pattern is 
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rougher and less ordered then for the other particle fraction. If the NPs are compared in 
single analysis as shown in Figure 6-24 the degradation pattern observed in the mixture, 
can be assigned to the different particles. cGNPs, shown in image a) and b), degrade in a 
fine structure and resists the electron beam relatively long. PLGA NPs in contrast form 
larger bubbles and start to degrade within seconds. This can be seen in c) and d). 
Polymers react differently to the energy brought into the system by an electron beam. 
Polymers with conjugated systems, such as aromatics, are more resistant than aliphatic 
structures.193 This can be explained because the excitation energy can be distributed by 
delocalized electrons. Furthermore, especially C-O-C bonds are broken easily. Both 
polymers investigated do not have a large delocalized electron system, nevertheless, with 
a small fraction of aromatic amino acids, like phenylalanine, the degradation of gelatin 
could be hindered slightly. The obtained small fragments diffuse out due to the high 
vacuum. In terms of thin samples, depressions arise. In thicker specimens bubbles are 
formed due to the polymer scission.193 Under electron beam radiation the polymer 
backbone is broken and free radicals occur because of the interaction between the 
polymers and the electron beam. These radicals can either interact with each other or 
initiate further reactions and thus enhance the breakages. Semi-crystalline polymers, like 
gelatin, exhibit two regions an amorphous one and a crystalline part. In crystalline phases 
polymer chains are packed closer and are more oriented. Therefore, they are less 
accessible to free radicals. In addition, radicals can even be trapped there. This so-called 
cage effect reduces the number of radical scissions and rises the stability against electron 
beam radiation.194 An additional effect stabilizing cGNPs in comparison to PLGA might be 
the covalent crosslinking. Even after backbone scission, the polymer fragment cannot 
diffuse out of the particle as it is still bound covalently through the sight chain. 
 
Figure 6-25: Cryo-TEM images of GNPs in PLGA showing core-shell-structure for particles of a size greater than 350 nm. 
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The composite particles made by GNPs and PLGA are imaged under the same conditions. 
As can be seen in Figure 6-25 NPs greater than 350 nm formed a clear shell with a 
thickness of 30 to 40 nm. The core-shell-structure stayed intact even after degradation in 
the electron beam. For smaller particles the shell is either too small to detect or it is not 
formed. From the degradation pattern it is not possible to assign which of the materials 
forms the shell and which one is positioned in the core. This might be because gelatin is 
not crosslinked here and therefore for sure reacts differently in the electron beam then 
the crosslinked reference particles. On the other hand the shell layer is relatively thin, so 
the exact degradation pattern is not accessible. At this point, it can be summarized that 
the polymer distribution striven for, the core-shell-model, is achieved for particles greater 
than 350 nm. 
6.3.4.3 Energy filtered TEM 
To assign which of the used polymers is forming the shell and which one is placed in the 
NP core, particles have been investigated in EFTEM. Because of the ice the contrast in 
cryo-TEM was too low to obtain a high enough contrast. Hence EFTEM was performed 
with dried samples at room temperature. Crosslinked GNPs have been used as reference 
system. 
 
Figure 6-26: EFTEM images of cGNPs a) in the bright field mode, b) the carbon map and c) the nitrogen map showing the 
distribution of the two elements. Scale bars are representing 0.5 µm. 
Figure 6-26 a) shows cGNPs in a BF-TEM image. Particles exhibit a low contrast to the 
background, as no enhancing staining was used and they melted in the electron beam. 
Nevertheless, the round shape was still visible. Except the one larger particle in the 
middle NPs show good particles size distribution. In b) and c) the carbon map and the 
nitrogen respectively are displayed. Both elements were distributed homogenously 
throughout the whole particle. In elementary analysis of gelatin the chemical composition 
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is determined to be carbon 50.5 %, oxygen 25.2 % whereas nitrogen only contributed 
with 17.0 % and hydrogen 6.8 %. This results in a brighter representation of carbon 195 in 
the EFTEM image. Switching from pure gelatin NPs to the composite particles we already 
know from cryo-TEM investigations we can expect a core-shell system at least for NPs 
with a diameter larger than 350 nm. Comparing the BF-image in Figure 6-27 a) and f) with 
the one from cGNP NPs in Figure 6-26, the formulation consisting of gelatin and PLGA 
occurs darker with a higher contrast to the background. This corresponds to results from 
cryo-TEM investigations where PLGA NPs showed the higher electron density. Looking at 
the BF images of GNPs in PLGA a difference in the electron density is visible. Going further 
to the carbon maps b) and g) particles occur very bright due to the high carbon 
percentage especially in PLGA. Carbon is distributed equally in all particles the same holds 
true for oxygen c) and h) with the deviation that oxygen is less present in both polymers. 
The nitrogen maps (Figure 6-27 d) and e)) attracts the highest interest as this is the 
element distinguishing the used substances, as it is only present in gelatin. As we know, 
gelatin makes up approximately 12 % in the used formulation and from this only a 
fraction of 17 % is nitrogen. Thus it is not surprising that nitrogen maps were relatively 
dark. Unfortunately, the images lost sharpness too. However, it was still clearly visible 
that for the particles showing the high electron density in the BF mode nitrogen showed 
circles and a very dark core. This means the outer layer is built by gelatin surrounding a 
PLGA NPs. The others, mostly smaller particles did not show this obvious core shell model 
but still consisted partly of gelatin. Either the resolution was too low to define the core 
shell structure or the smaller particles actually exhibit a mixture throughout the whole 
particle. As Figure 6-27 e) shows a big particle, which seems to have a homogenous 
gelatin distribution this seems to be more likely for the small particles too. 
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Figure 6-27: EFTEM Images of GNPs in PLGA of two representative areas on the sample grid. Showing the brightfield 
image in a) and f). b) and g) represent the carbon distribution. Oxygen map images are c) and h) and nitrogen, the 
element distinguishing the polymers is shown in d) and e).  
The knowledge about the formulation gained in EFTEM studies have been reviewed with 
a pH titration curve measuring the ζ-potential. Hence gelatin as polypeptide exhibits a 
type dependent isoelectric point, the polarity of NPs with a gelatin shell should inverse in 
dependency to the pH. Values ranging from 8 to 3 have been tested. In Figure 6-28 they 
are plotted to the corresponding ζ-potential. 
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Figure 6-28: pH dependent ζ-potential of GNPs in PLGA particles showing the inversion from negative to positive signs 
with an IEP between pH 5 to 6. The blue line represents PLGA NPs changing the ζ-potential but not turning the sign. 
The ζ-potential increased from – 20 mV to + 25 mV with a decreasing pH. From the graph 
an IEP (at neutral surface charge) around pH 5.5 was determined. PLGA NPs and cGNPs 
were used as reference. PLGA in blue changed the surface charge too but did not get 
neutral or positive. cGNPs changed the charge in the same way as GNPs in PLGA. These 
results support the findings from the EFTEM investigations. During the production process 
gelatin seems to be dissolved again and rearranged surrounding the PLGA NPs. The most 
probable step for this phase inversion is the solvent evaporation time. Gelatin can be 
dissolved by the aqueous PVA solution and thus diffuses out of the NPs formulation 
before the PLGA droplet hardens due to the solvent evaporation. In this way, most of the 
particles form solid PLGA NPs with a gelatin shell. This could explain as well the high burst 
release of approximately 30 % and the low loading capacity for FITC-dextrans too. 
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6.4 Conclusion 
It was possible to design a crosslinking free carrier system based on gelatin and PLGA, 
which is exclusively composed by biodegradable, biocompatible and non-toxic materials. 
This is important for the delivery of the growing amount of biotherapeutics. The obtained 
NPs have a narrow size distribution with a mean hydrodynamic diameter of 250 nm and a 
negative surface charge of approximately -20 mV at neutral pH. The new hydrophilic 
platform technology could be proven to be nontoxic in cell viability studies. Furthermore, 
by the variation of the used gelatin amount, the hydrophilic part can be tuned. For LNA 
very good encapsulation efficiencies could be achieved. In further studies, with plasmid 
coding for eGFP loaded NPs, the suitability of the system as non-viral transfection vector 
could be demonstrated. Here is a great potential for the delivery system even though, it 
was in the end proven to be composed by a PLGA core surrounded by a gelatin shell. The 
encapsulation of larger molecules, like FITC-dextran70, was unfortunately not sufficient. 
For the purpose of a non-viral transfection vector the achieved loading was high enough, 
what can be seen from the results described in chapter 6.3.3.2. In confocal laser 
microscopy studies with fluorescently labelled materials a colocalization could be shown. 
However, the resolution of CLSM is not high enough for a detailed material separation. 
The use of the innovative EFTEM technique enabled the exact structure determination. To 
our knowledge EFTEM was used for the first time to exactly investigate the distribution of 
two organic polymers in the nanometer scale. In this way, the phase inversion during the 
preparation process was detected and underlined by the investigation of a pH dependent 
ζ-potential measurement. By the establishment of the unique analytical method 
combination a further development of the platform and the investigation in possibilities 
to force the gelatin to stay inside the PLGA NPs can be envisaged. Even though the 
polymer distribution is exactly opposite to what was intended, it could be shown as 
effective carrier for transfection studies. 
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7 Outlook 
7.1 Elasticity of Crosslinked Gelatin Nanoparticles 
The change in the elastic moduli over the storage time should be further investigated. For 
the development of an applicable GNP formulation the hardening has to be monitored 
over a longer time. The question which should be addressed in this regard is, if after a 
certain time Young’s moduli stay constant and a plateau is reached, or not. This should 
have an impact on the in vivo fate after usual storage times between preparation and 
application. A second parameter, which can be considered to be examined, is the 
influence of the storage conditions. It could be shown, that hardening of gelatin gels takes 
place at a faster rate at lower temperatures.196 Storage at room temperature might slow 
down the increase of Young´s moduli and therefore, slow down the hardening process. In 
order to investigate the influence of shorter crosslinking times alternative purification 
methods need to be established. The agglomeration after centrifugation of cGNPs, 
prepared with crosslinking of less than three hours, could be prevented by the use of 
cross flow filtration or dialysis. The irreversible formation of aggregates might come from 
the softness of these particles, which could be very interesting in terms of the design of 
long circulating cGNPs. A comparison with GNPs crosslinked only in the area of an outer 
shell, like it could be achieved in our laboratory with N,N'-diisopropylcarbodiimide would 
be of interest. By the limitation of the crosslinking to the outside of the particles, it is 
assumable to form softer particles, than by crosslinking the whole particle matrix. In 
regard to the interaction of cells with cGNPs shorter and longer incubation times should 
be examined as well as a collection of more data per time point. When enough time 
points are measured in a quantitative way, the calculation of in vitro kinetics and a 
correlation to the measured Young´s moduli could be very interesting. Macrophage 
uptake would be an important information to obtain, as many particle systems are 
cleaned from the blood circulation by cells of the MPS.108 After these experiments, by 
which the knowledge of the mechanical properties and their influences to in vitro systems 
can be increased, the evaluation of the in vivo fate of soft and hard NPs would be a very 
interesting aspect. 
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7.2 Gelatin Nanoparticles in PLGA 
The resulting NPs system, having PLGA NPs coated by gelatin can be further investigated, 
like for example for the co- delivery of hydrophobic and hydrophilic drugs. This is an 
increasing trend, especially used in cancer treatment.197 Another possible benefit of the 
gelatin core is the formation of a softer particle system. This could be investigated by the 
nanoindentation method with SPM, which is described in detail in chapter 5.2.5.3. Softer 
particles in general prolong the half-life time and alter the NP distribution into organs.9 In 
addition, gelatin could provide the possibility of a chemical modification by the functional 
groups, and in this way could be used for an active drug targeting. Another possibility is a 
further formulation development with the aim to actually achieve GNPs coated by PLGA 
and monitored by the established analytical methods. By the use of co-solvents PLGA 
could be forced to form a solid shell around the GNPs before the formation of the 
emulsion. Pentane, an antisolvent for PLGA, could be used for this approach. First 
preliminary experiments showed the potential of this attempt. ζ-potential still turned 
positive at lower pH values, but much less than for NPs prepared by the standard 
protocol. A challenging part in this approach is to maintain the size range constant. 
Samples prepared in this way had a very broad size distribution and were interspersed 
with microparticles of several tenths of micrometers. A second possibility would be the 
exchange of the emulsifying step by a second precipitation. In this way first gelatin would 
be precipitated and, after mixing the freshly prepared GNPs with dissolved PLGA, they 
would be co precipitated. When the second solvent is chosen in a way that gelatin is 
insoluble too, GNPs should be stable and the phase inversion could be hindered. 
Changing the temperature and transferring the process into an ice bath could prevent the 
liberation of gelatin. By gelling the freshly prepared particles they could be solidified until 
a stable PLGA layer is formed, which is stabilizing them in a sufficient way. To evaluate the 
interaction between gelatin and PLGA it would be a possibility to go one step back and 
investigate in the coating of cGNPs. This could be interesting as well in regard to an 
altered release compared with blank cGNPs. A hydrophobic shell should prolong the 
release of hydrophilic drugs in a significant way. This results in larger application intervals 
what is beneficial in terms of patient’s compliance. 
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Chemical Name Comment Supplier 
4´,6-Diamidino-2-phylindol  DAPI Sigma, Aldrich GmbH, Selze, Germany 
A459 cells  ATCC, LGC Standards GmbH, Wesel 
Acetone Analytical reagent grade Fischer Chemical Ltd., Loughborough, U.K. 
Caso-Agar   
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Dimethylformamide  Sigma Aldrich GmbH, Steinheim, Germany 
Dimethylsulfoxid  
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Dodecylamine  Sigma Aldrich GmbH, Steinheim, Germany 
D-sorbitol  Sigma Aldrich GmbH, Steinheim, Germany 
Dulbecco´s Modified Eagle 
Medium  
DMEM Gibco - Thermo Fisher, Carlsbad, US 
EndoFree Plasmid Mega Kit No.: 12381 Qiagen, Venlo, Netherlands 
Ethanol > 99.8% Sigma Aldrich GmbH, Steinheim, Germany 
Ethyl acetate  Sigma Aldrich GmbH, Steinheim, Germany 
Fetal calf serum  Lonza, Basel, Switzerland 
FITC-Dextran
70
   TdB Cons., Uppsala, Sweden)  
Gelatin A Bloom 175 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Gelatin B  Bloom 75 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Glutamine  Gibco - Thermo Fisher, Carlsbad, US 
Glutaraldehyde  Sigma-Aldrich GmbH, Steinheim, Germany 
HBSS Buffer  
Sigma Aldrich Life Science GmbH, Seelze, 
Germany 
HCl 37% Bernd Kraft, Duisburg, Germany 
HEK293T cells  ATCC, LGC Standards GmbH, Wesel 
MTT reagent  
Sigma Aldrich Life Science GmbH, Seelze, 
Germany 
N-Hydroxysuccinimid Alexa 
Flour® 633 
 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
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Poloxamer 188  AppliChem, Darmstadt, Germany 
Polyethylenimide ~ 25 kDa Sigma Aldrich GmbH, Steinheim, Germany 
Polylactic-co-glycolicacid Resomer RG 503 H 
Evonik Nutrition & Care, Darmstadt, 
Germany 
Polyvinylalcohol  
Kururay Europe GmbH, Hattersheim am 
main, Germany 
QuantiPro
TM
 BCA Assay Kit  Sigma Aldrich, Munich, Germany 
RPMI-1640 medium   
Sigma Aldrich Life Science GmbH, Seelze, 
Germany 
Sodiumhydroxid > 99% p.a. 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Tetramethyl-rhodamine 
isothiocyanate dextran 
TRITC-dextran TdB Cons., Uppsala, Sweden)  
Triton X-100  
Sigma Aldrich Life Science GmbH, Seelze, 
Germany 
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Device Type Company 
Particle Production   
Autoclave FVS/2 
Fedegari, Integra Biosciences, now ibs 
Tecnomara, Fernwald, Germany 
Centrifuge  
Thermo Fisher Scientific, Osterode am harz, 
Germany 
Freeze dryer Alpha 2-4 LSC 
Martin Christ Gefriertrocknungsanlagen 
GmbH, Osterode am Harz, Germany 
Laminar airflow work bench Technoflow 2F120-II GS 
Integra Biosciences AG, now ibs tecnomara 
GmbH, Fernwald, Germany 
Petri dishes  
Greiner bio-one GmbH, Frickenhausen, 
Germany 
Plate reader Infinite®M200 Tecan group Ltd., Männedorf, Switzerland 
Ultrasound bath Elmasonic P Elma Schmidbauer GmbH, Singen, Germany 
UltraTurrax UltraTurrax T25 
IKA®-Werke GmbH & CO. KG, Staufen, 
Germany 
UltraTurrax Disperser S 25 N – 8 G 
IKA®-Werke GmbH & CO. KG, Staufen, 
Germany 
96-well plates  
Greiner bio-one GmbH, Frickenhausen, 
Germany 
Size & ζ-Potential   
Zetasizer Nano ZS Malvern Instruments Ltd, Malvern, UK 
Capillary Cell DTS 1070 Malvern Instruments Ltd., Malvern, UK 
Scanning Electron 
Microscopy 
  
Scanning Electron 
Microscope (HIPS) 
EVO HD15 
Carl Zeiss Microscopy GmbH, Jena, 
Germany 
Sputter Coater (HIPS) Quorum Q150R ES 
Quorum Technologies Ltd., East Grinstead, 
UK 
Scanning Electron 
Microscope (WZMW) 
JEOL JSM-7500F  JEOL, Tokyo, Japan 
Sputter Coater (WZMW) Edwards S150 Edwards, West Sussex, United Kingdom 
Carbon Disk  Plano, Wetzlar, Germany 
Pin tube  Plano, Wetzlar, Germany 
Silica wafer  Plano, Wetzlar, Germany 
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Transmission Electron 
Microscopy 
  
Transmission Electron 
Microscope 
Joel JEM 2100 JEOL, Tokyo, Japan 
TEM Camera Gatan Orius SC100  Gatan Inc., Pleasanton, CA, United States 
Cryoplunger Gatan CP3 Gatan Inc., Pleasanton, CA, United States 
Cryo-TEM holder Gatan 914 Gatan Inc., Pleasanton, CA, United States 
Gatan image filter GIF 2002 Gatan Inc., Pleasanton, CA, United States 
Slow-scan camera Gatan model 850 Gatan Inc., Pleasanton, CA, United States 
Holey Carbon Film S147-4 Plano, Wetzlar, Germany 
Scanning Probe Microscopy   
Scanning Probe Microscope JPK NanoWizard I JPK Instruments, Berlin, Germany 
SPM Tip Force 
measurements 
MLCT, Cantilever C Bruker Nano Inc., Camarillo, United States 
SPM Tip (in air) OMCL-AC160TS Olympus Org, Tokyo, Japan 
JPK-SPM Data Progressing 
Program 
 JPK Instruments, Berlin, Germany 
UV/Ozone cleaner UV/Ozone ProCleaner
TM
 
BioForce Nanosciences Inc., Ames, Iowa, 
United States 
Cellculture & CLSM   
Scanning Confocal Microscope (Particle Interaction) Carl Zeiss AG, Jena, Germany 
Scanning Confocal 
Microscope (Colocalization) 
Axiovert 100M  Carl Zeiss AG, Jena, Germany 
Laser Axiovert 100M  Lasos Lasertechnik GmbH, Jena, Germany 
Cellculture Microscopy 
Chambers 
ibiTreat® Ibidi GmbH, Martinsried, Germany 
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Figure 3-1: Prominent application routes in drug delivery. Adopted from: “Toxicology and clinical 
potential of nanoparticles”13, Copyright © 2011 Elsevier Ltd. .................................................. 5 
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Reprinted with permission from: ”Targeting of gastrointestinal tract for amended delivery of 
protein/peptide therapeutics: Strategies and industrial perspectives“,17 Copyright © 2014 
Elsevier B.V. ............................................................................................................................... 6 
Figure 3-3: Structure of the skin with their three layers (Epidermis, dermis and subdermal tissue). 
Three possible drug penetration routes are drawn in the figure (1: appendageal, 2: 
transcellular, 3: intercellular). Reprinted from: “Nanoparticle-Enabled Transdermal Drug 
Delivery Systems for Enhanced Dose Control and Tissue Targeting”26 (CC BY 4.0) .................. 7 
Figure 3-4: Fate of aerosols after pulmonary application. 1) Contact with lung fluid and drug 
release. 2) API absorption through the epithelium. 3) Undissolved particles can be cleared by 
macrophages or mucociliary clearance. Modified with permission of: “Pulmonary drug 
delivery: from generating aerosols to overcoming biological barriers—therapeutic 
possibilities and technological challenges”41 Copyright © 2013 Elsevier Ltd. .......................... 9 
Figure 3-5: Partial hydrolysis of collagen, here by heat; the macromolecular changes are in good 
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Figure 3-9: Possible strategies in carrier design for a targeted delivery in therapy and diagnostics. 
Reprinted from: “Strategies for the intracellular delivery of nanoparticles”,94 Copyright © 
2010 Royal Society of Chemistry ............................................................................................. 18 
Figure 3-10: Possible cellular uptake mechanisms depending on the particle size. Reprinted from: 
“Targeting receptor-mediated endocytic pathways with nanoparticles: Rationale and 
advances”, Copyright © 2012 Elsevier B.V. ............................................................................. 19 
Figure 3-11: Colored SEM images of macrophages in brown and microparticles in purple. a) 
Elliptical disks which got in contact with the high curvature side. (Scale bar = 10 µm.) b) A 
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macrophage attached to the flat side and is not able to phagocyte the disk. (Scale bar = 
5 µm) and c) is showing a spherical microparticle after half phagocytosis. (Scale bar = 5 µm) 
Reprinted from: “Particle shape: A new design parameter for micro- and nanoscale drug 
delivery carriers”112 Copyright © 2007 Elsevier B.V. ............................................................... 21 
Figure 3-12: Common surface functionalization methods to enhance the efficacy of nanoparticles 
in drug delivery and diagnostics by a targeted NP delivery and prolonged blood circulation. 
Reprinted from: “Revisiting 30 years of biofunctionalization and surface chemistry of 
inorganic nanoparticles for nanomedicine”125 Copyright © 2014 Conde, Dias, Grazú, Moros, 
Baptista and de la Fuente; ....................................................................................................... 23 
Figure 3-13: Model of the uptake of rigid NPs in a) and soft NPs in b) showing the particle 
deformation during cell wrapping for soft particles. Rigid particles are completely 
internalized whereas soft counterparts are trapped at the cell surface. From “Tunable 
Rigidity of (Polymeric Core)–(Lipid Shell) Nanoparticles for Regulated Cellular Uptake”137 
Copyright © 1999 - 2017 John Wiley & Sons, Inc. ................................................................... 25 
Figure 4-1: Overview over the four milestones addressed in the present thesis. ........................... 27 
Figure 5-1: Construction of a DLS measurement device with its characteristic components. 
Reprinted from: “DLS and zeta potential – What they are and what they are not?”146 
Copyright: © 2016 Elsevier B.V ............................................................................................... 31 
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How stuff works ....................................................................................................................... 32 
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forces. ...................................................................................................................................... 37 
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smooth surface. ....................................................................................................................... 42 
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Figure 6-1: Chemical structure of poly lactic-co-glycolic acid. The ratio between glycolic acid 
(marked with the y) and lactic acid, (signed with the x) can vary. .......................................... 48 
Figure 6-2: Reduction of copper II to copper I by proteins and formation of a complex with 
bicinchoninic acid under alkaline conditions .......................................................................... 50 
Figure 6-3: Demands on the solvents to their behavior towards gelatin, stabilizers, PLGA and to 
each other ............................................................................................................................... 51 
Figure 6-4: Production scheme of GNPs in PLGA. Gelatin is dissolved and subsequently 
precipitated in a stabilizer containing antisolvent. The obtained NPs are mixed with a PLGA 
solution. This mixture is then emulsified in a 2 % aqueous PVA solution. If drugs are 
incorporated, they have been co-precipitated ....................................................................... 52 
Figure 6-5: Reaction of the tetrazolium salt MTT to formazan during the cell viability test ........... 54 
Figure 6-6: Structure of LNA in the β-D-ribo configuration ............................................................. 56 
Figure 6-7: Decay of 32P into 32S by β—decay .................................................................................... 56 
Figure 6-8: The three possible structures postulated for the standard formulation. The white part 
with blue lines indicates gelatin, the solid blue area represents PLGA. ................................. 59 
Figure 6-9: Scattering possibilities of electrons after interacting with the specimen ..................... 60 
Figure 6-10: Core-loss area of an electron energy loss spectrum of crosslinked gelatin 
nanoparticles showing the carbon and nitrogen edges. ......................................................... 62 
Figure 6-11: Hydrodynamic diameters and PdIs of GNPs in PLGA with DDA as stabilizer in 
dependency of the homogenization time a) one minute, b) three minutes and c) 5 minutes 
and the number of centrifugation steps for purification. ....................................................... 64 
Table 6-1: Formulation development with different nonsolvents and stabilizers. Acetone and DMF 
in an equal mixture together with poloxamer 188 showed the best results in all tests and 
therefore was set as standard formulation. ............................................................................ 65 
Table of Figures   
XXX 
Figure 6-12: Images of GNPs in PLGA standard formulation in SEM a) and displayed in a closer 
view in SPM height 2D image in b) with the belonging 3D height image in c) and a cross-
section in d). The cut through the NPs for the cross section is marked in b). It shows the 
spherical particle shape with a diameter of around 175 nm and a height of 115 nm. ........... 66 
Figure 6-13: Gelatin release of GNPs in PLGA with different nonsolvents and stabilizer over 6 days. 
Gelatin content is determined by BCA assay. .......................................................................... 67 
Figure 6-14; Sizes and PdI of GNPs in PLGA prepared with different gelatin solvents. Most 
formulations showed a hydrodynamic diameters around 250 nm and a narrow particle size 
distribution with a PdI below 0.2. ............................................................................................ 68 
Table 6-2: Different gelatin to PLGA ratios and the respective NP characteristics .......................... 69 
Figure 6-15: SEM image of particles made by a gelatin to PLGA ratio of 1:1.25 in a) and 1:0.625 in 
b). ............................................................................................................................................. 69 
Figure 6-16: Gelatin A NPs in PLGA a) Hydrodynamic diameter and PdI and b) ζ-potential. Both 
parameters are compared to gelatin B NPs (Gelatin B) in PLGA and pure PLGA NPs. ............ 70 
Figure 6-17: Cell viability after 4 h incubation on A549 cells tested by MTT assay. All tested 
concentrations are in the as nontoxic considered range. ....................................................... 72 
Figure 6-18: Morphology of LNA loaded GNPs in PLGA in SEM (a) and in an SPM height image (b).
 ................................................................................................................................................. 73 
Figure 6-19: a) Encapsulation efficiency of radioactive labelled LNA in GNPs in PLGA in different 
LNA concentrations and b) hydrodynamic diameters and PdI´s of LNA loaded NP 
formulations. ........................................................................................................................... 73 
Figure 6-20: Sterility test on agar plates after 120 h of incubation at 37°C a) GNPs in PLGA before 
freeze drying, b) GNPs in PLGA after freeze drying with sorbitol as cryoprotector and c) a 
positive control with a contaminated solution........................................................................ 74 
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12 Index of Abbreviations 
A Contact area 
ɑ  Tip half angle 
ɑ
-1
 Distribution half-life 
AFM Atomic force microscope 
API Active pharmaceutical ingredient 
Arg / R Arginine 
Asp / D Aspartic acid 
BCA assay Bicinchoninic acid assay 
BE Back scattered electrons 
BF Brightfield 
CCD Charge couple device 
cGNPs Crosslinked gelatin nanoparticles 
CLSM Confocal scanning microscope 
cpm Counts per minute 
D Diffusion coefficient 
DAPI 4′,6-Diamidine-2′-phenylindole dihydrochloride 
DDA Dodecylamine 
DDS Drug delivery system 
D
H Hydrodynamic diameter 
DLS Dynamic light scattering 
DMEM Dulbecco´s Modified Eagle Medi 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DP Data Progressing Program 
E Young´s modulus 
EELS Electron energy loss spectroscopy 
EFTEM Energy filtered TEM 
eGFP Enhanced green fluorescent protein 
EPR Enhanced permeation and retention 
F Applied force 
FA-PLGA Fluorescein amine labelled PLGA 
FCS Fetal calf serum 
FDA U.S. food and drug administration 
FITC Fluoresceinisothiocyanat 
GIT Gastro intestinal tract 
Gly / G Glycine 
GNPs Gelatin nanoparticles 
h
c Contact depth 
HIPS Helmholtz Institute for Pharmaceutical Research Saarland 
HMVEC Human lung microvascular endothelial cells 
HUVEC Human umbilical vein endothelial cells 
IEP Isoelectric point 
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k Spring constant 
k
B Boltzmann constant 
l
0 Initial NP height 
LaB
6 Lanthanum hexaboride 
LDV Laser Doppler velocimetry 
LEI Lower secondary electron image 
LNA Locked nucleic acid 
M3 Mixed mode measurement 
MPS Mononuclear phagocyte system 
MTT 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
ƞ Viscosity 
NIBS Non-invasive back-scatter technology 
NPs Nanoparticles 
PALS Phase analysis light scattering 
PdI Polydispersity Index 
PEG Polyethylenglycole 
PEGDA Poly(ethylene glycol) diacrylate 
PEI Polyethylenimine 
PLGA Poly(lactic-co-glycolic acid) 
PRINT Particle replication in nonwetting templates 
PSPD Position-sensitive photodiode 
PVA Polyvinylalcohol 
RBCs Red blood cells 
RPMI Roswell Park Memorial Institute 
SEI Secondary electron image 
SEM Scanning electron microscopy 
SPM Scanning probe microscope 
T Temperatur 
TEM Transmission electron microscopy 
T
max Maximum plasma concentration 
TRITC Tetramethyl-rhodamine isothiocyanate 
z Piezo displacement 
ZD Z-average diameter 
β
-1
 Elimination half-life 
δ
c Cantilever deformation 
Δl Indentation depth 
ν Possion´s ratio 
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